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ABSTRACT
Objectives To determine factors associated with 
COVID-19- related death in people with rheumatic 
diseases.
Methods Physician- reported registry of adults with 
rheumatic disease and confirmed or presumptive 
COVID-19 (from 24 March to 1 July 2020). The primary 
outcome was COVID-19- related death. Age, sex, smoking 
status, comorbidities, rheumatic disease diagnosis, 
disease activity and medications were included as 
covariates in multivariable logistic regression models. 
Analyses were further stratified according to rheumatic 
disease category.
Results Of 3729 patients (mean age 57 years, 68% 
female), 390 (10.5%) died. Independent factors 
associated with COVID-19- related death were age 
(66–75 years: OR 3.00, 95% CI 2.13 to 4.22; >75 
years: 6.18, 4.47 to 8.53; both vs ≤65 years), male 
sex (1.46, 1.11 to 1.91), hypertension combined with 
cardiovascular disease (1.89, 1.31 to 2.73), chronic 
lung disease (1.68, 1.26 to 2.25) and prednisolone- 
equivalent dosage >10 mg/day (1.69, 1.18 to 2.41; vs 
no glucocorticoid intake). Moderate/high disease activity 
(vs remission/low disease activity) was associated with 
higher odds of death (1.87, 1.27 to 2.77). Rituximab 
(4.04, 2.32 to 7.03), sulfasalazine (3.60, 1.66 to 7.78), 
immunosuppressants (azathioprine, cyclophosphamide, 
ciclosporin, mycophenolate or tacrolimus: 2.22, 1.43 to 
3.46) and not receiving any disease- modifying anti- 
rheumatic drug (DMARD) (2.11, 1.48 to 3.01) were 
associated with higher odds of death, compared with 
methotrexate monotherapy. Other synthetic/biological 
DMARDs were not associated with COVID-19- related 
death.
Conclusion Among people with rheumatic disease, 
COVID-19- related death was associated with known 
general factors (older age, male sex and specific 
comorbidities) and disease- specific factors (disease 
activity and specific medications). The association with 
moderate/high disease activity highlights the importance 
Key messages
What is already known about this subject?
 ► To date, most available data on outcomes 
for people with rheumatic diseases infected 
with SARS- CoV-2 come from single centre or 
single country case series or from one large 
international registry; the COVID-19 Global 
Rheumatology Alliance (GRA) physician registry.
 ► The first GRA publication identified factors 
associated with higher odds of COVID-19 
hospitalisation, including older age, presence 
of comorbidities and higher dosages of 
glucocorticoids (≥10 mg/day of prednisolone 
equivalent).
 ► Clinical outcome information on patients 
with COVID-19 who have rheumatic disease 
therefore remains limited, particularly with 
regard to factors associated with COVID-19- 
related death.
What does this study add?
 ► In this analysis of 3729 patients with 
rheumatic diseases, older age, male sex, and 
cardiovascular and chronic lung disease were 
associated with COVID-19- related death.
 ► Disease- specific factors, namely, moderate/
high disease activity and certain 
medications (rituximab, sulfasalazine 
and immunosuppressants (as opposed to 
immunomodulators like disease- modifying 
anti- rheumatic drugs (DMARDs)) were also 
associated with COVID-19- related death.
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of adequate disease control with DMARDs, preferably without 
increasing glucocorticoid dosages. Caution may be required with 
rituximab, sulfasalazine and some immunosuppressants.
INTRODUCTION
There is a lack of robust data to inform our understanding of 
outcomes following SARS- CoV-2 infection in patients with 
inflammatory rheumatic diseases, leading to uncertainties 
regarding chronic disease management, especially for those 
taking immunosuppressant or immunomodulatory drugs.1–3
Whether people with rheumatic diseases belong to a vulner-
able, higher risk population for SARS- CoV-2 infection and have 
poorer outcomes is unclear.1–8 In general, this population seems 
to have similar or only slightly poorer outcomes compared 
with those without rheumatic disease.7–9 However, important 
confounding disease- related factors, such as disease activity or 
treatments, have previously not been addressed.
Medications commonly used to treat rheumatic diseases have 
been used or are being tested for the prevention and/or treatment 
of COVID-19 and its complications,10 raising questions about 
the impact of these treatments on the outcomes of SARS- CoV-2 
infection. Continuation of immunomodulatory or immunosup-
pressive therapy is essential for controlling rheumatic disease 
activity, avoiding disease progression and preventing joint or 
organ- damage related to sustained inflammation. Withdrawal of 
effective treatments should be based on sound evidence, even 
during a pandemic.
To generate more granular data relevant to rheumatic diseases, 
a global network of rheumatologists, data scientists and patients 
developed a COVID-19 physician- reported case registry in 
March 2020.11 12 Analysis of the first 600 patients revealed 
that older age and comorbidities were associated with hospital-
isation,13 similar to results in the general population.8 14 More 
robust data on the risk of poor outcomes, in particular risk of 
death, are required.
The aim of this study was to investigate factors associated with 
COVID-19- related death in patients with rheumatic diseases and 
to analyse these associations by disease group.
METHODS
Data source
The COVID-19 Global Rheumatology Alliance (C19- GRA) 
physician- reported registry is an observational registry launched 
on 24 March 2020. Data are entered voluntarily by rheuma-
tologists or under supervision of rheumatologists; patients 
are eligible for inclusion if they have a pre- existing rheumatic 
disease and a COVID-19 diagnosis. Data are entered either 
directly into the global or European data entry systems or trans-
ferred from national registries (France, Germany, Italy, Portugal 
and Sweden).
We used data collected on or before 1 July 2020. Further 
details of this registry have been described elsewhere.11–13 Coun-
tries were assigned to the six WHO regions ( www. who. int); 
the ‘Americas’ was further divided into north and south. Given 
the registry collects anonymous data, the UK Health Research 
Authority and the University of California San Francisco Institu-
tional Review Board considered it exempt from patient consent.
Patient stratification into diagnostic groups
Rheumatic diseases differ regarding the disease- modifying anti-
rheumatic drugs (DMARDs) approved for their treatment. To 
minimise the impact of this heterogeneity on the associations of 
interest, in addition to the main analysis with all patients, diag-
nostic categories were defined (figure 1) and stratified analyses 
were undertaken for patients with (1) inflammatory joint diseases 
(IJD), (2) rheumatoid arthritis (a subset of the IJD subgroup) and 
(3) connective tissue diseases (CTD)/vasculitis.
COVID-19 reporting and outcome
Both confirmed and presumptive cases of COVID-19 were 
reported. The method of COVID-19 diagnosis was specified: 
PCR, CT scan, metagenomic testing, laboratory assays or based 
on symptoms only.
For analysis, patients were subsequently categorised into 
(1) confirmed or high likelihood of COVID-19 (chest imaging 
(CT or chest X- ray) showing bilateral infiltrates and/or symp-
toms after close contact with a known laboratory- confirmed 
COVID-19 positive patient) or (2) presumptive cases based on 
symptoms alone.
The primary outcome was COVID-19- related death.
Treatment prior to COVID-19
Antirheumatic medications used prior to COVID-19 diagnosis 
were categorised into groups shown in figure 1. Immunomodu-
latory drugs (conventional synthetic (cs)/biological (b)/targeted 
synthetic (ts) DMARDs) were distinguished from immunosup-
pressive drugs (azathioprine, cyclophosphamide, ciclosporin, 
mycophenolate mofetil/mycophenolic acid, tacrolimus) as 
recommended by Isaacs and Burmester15; glucocorticoids are 
also immunosuppressive but they were examined separately and 
categorised by prednisolone- equivalent dosage (1–10 mg/day 
and >10 mg/day). Methotrexate monotherapy was adopted as 
the medication reference group; methotrexate is the anchor drug 
in multiple rheumatic diseases16 and it represents the largest 
medication category in the registry.
Statistical analyses
Descriptive tables were produced for the whole cohort and then 
by diagnostic group, country (for the six countries with the 
highest number of cases: France, Germany, Italy, Spain, UK and 
USA) and medication. Independent associations between demo-
graphic and disease features and COVID-19- related death were 
estimated using multivariable logistic regression and reported as 
OR and 95% CI. Covariates included in the model were age, sex, 
key comorbidities (hypertension alone or cardiovascular disease 
(CVD) alone, hypertension combined with CVD, chronic lung 
disease, chronic kidney disease (CKD) and diabetes), smoking 
status (ever vs never), rheumatic disease diagnostic group, 
disease activity as per the physician’s global assessment (severe/
high or moderate disease activity vs minimal/low disease activity 
or remission), rheumatic disease treatment prior to COVID-19 
diagnosis and prednisolone- equivalent glucocorticoid use.
Key messages
How might this impact on clinical practice or future 
developments?
 ► There is differential risk of COVID-19- related death according 
to disease activity and treatments in patients with rheumatic 
disease, highlighting the need for adequate disease 
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All patients with confirmed or presumptive COVID-19 were 
included in the main analyses. Patients with missing primary 
outcome (N=82) or missing values for age, sex and DMARD 
(N=19) were excluded from analysis. Missing values for comor-
bidities, smoking status, glucocorticoid therapy and disease 
activity were derived by multiple imputation using full condi-
tional specification.17 Results of the logistic regression analyses 
for 10 imputed datasets were pooled by Rubin’s rules. As disease 
activity was missing for all French patients, country- level life 
expectancy was used in the imputation model to explain poten-
tial structural differences in disease activity between countries 
not accounted for in the patient- level data (data from 2018, 
source: http:// hdr. undp. org/).
To account for pronounced heterogeneity between partici-
pating countries regarding both healthcare systems and infection 
dynamics, countries were implicitly considered as data clusters 
in the regression analysis by assuming that the data arose from a 
cluster sample design; this was done by applying a Taylor series 
linearisation in the variance estimation.18
For patients listed as having more than one rheumatic disease 
or being treated with more than one of the medications of 
interest, we created a hierarchy based on clinical expertise to 
categorise patients. This process creates disjoint categories, 
allowing a clear reference group for interpretation of the regres-
sion models and avoiding collinearities. Patients with more than 
one of the following diseases were grouped according to the 
following hierarchy: systemic lupus erythematosus (SLE)>vas-
culitis>other CTD>RA>psoriatic arthritis (PsA)>(other) 
spondyloarthritis (SpA)>other IJD>other non- IJD/non- CTD 
rheumatic disease. Patients receiving multiple csDMARDs or 
immunosuppressants (except glucocorticoids) were grouped 
according to the following hierarchy: immunosuppressants>-
sulfasalazine>antimalarials>leflunomide>methotrexate. 
Patients receiving a b/tsDMARD were considered solely in the 
b/tsDMARD group. Patients treated with more than one b/
tsDMARD (N=4), patients receiving IL-1 inhibitors (N=20) and 
patients receiving DMARDs atypical for their disease subgroup 
(N=48) were excluded from analysis due to very low numbers 
(figure 2). Patients were excluded from a particular analysis if the 
medication they received provided ≤20 patients for that analysis 
or if there were no deaths reported for that specific medication.
The following sensitivity analyses were performed to examine 
the robustness of our findings to procedures for handling missing 
data: (1) excluding patients from France (no disease activity data 
available); (2) complete case analysis. Further sensitivity analyses 
were conducted to assess the stability of the results: (1) limited 
to patients with confirmed or highly likely COVID-19; (2) using 
the alternative outcome ‘death or invasive ventilation’; (3) using 
a reduced number of covariates to assess the risk of overfitting; 
(4) analysis explicitly controlling for country, using data from 
the top six reporting countries; (5) analysis stratified for several 
binary key variables (age >65 or not, sex, ever smoked vs not, 
high/moderate/severe disease activity vs remission/low disease 
activity, CVD, chronic lung disease, glucocorticoid use) to assess 
the possibility of interactions.
Data were considered statistically significant for p values 
<0.05. All analyses were conducted in SAS (V.9.4) and R 
(V.3.6.3).
RESULTS
As of 1 July 2020, 3830 patients were in the registry, of whom 
3729 had no missing values for death, age, sex and DMARD 
therapy (table 1, results for all patients; online supplemental 
table 1, results stratified by diagnostic subgroup; online supple-
mental table 2, results stratified by country; online supplemental 
table 3, results stratified by medication of interest).
Patient characteristics and outcomes of COVID-19
Mean age was 57 (15.7) years and most patients were ≤65 years 
(2586/3729, 69.3%) and female (2534/3729, 68%). The most 
common disease was RA (1394/3729, 37.4%), followed by CTDs 
other than SLE (533/3729, 14.3%), SLE (391/3729, 10.5%), 
PsA (440/3729, 11.8%) and other SpA (431/3729, 11.6%).
Patients were primarily from Europe (2315/3729, 62.1%) or 
North America (1105/3729, 29.6%). Nearly half (1309/2758, 
47.5%) had minimal or low disease activity and one- third 
(893/2758, 32.4%) were in remission before COVID-19. One- 
quarter of all patients (776/3164, 24.5%) were ever smokers.
Most patients had a laboratory- confirmed diagnosis of 
COVID-19 (2897/3729, 77.7%); 2.4% (91/3729) had a 
high likelihood of infection based on imaging or confirmed 
COVID-19 contacts.
Death occurred in 10.5% (390/3729) of patients; 68.7% 
(268/390) of those who died were >65 years. Nearly half of all 
patients (1739/3546; 49.0%) were hospitalised. Invasive ventila-
tion was reported in 6.2% (187/2995) of patients, but in 40.8% 
(120/294) of those who died.
Figure 1 Disease and medication groups. ANCA, anti- neutrophil 
cytoplasm antibodies; DMARD, disease- modifying antirheumatic drugs; 
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Comorbidities
Most patients (2582/3700, 69.8%) had at least one comorbidity, 
and 20.5% (760/3700) had more than three. The most frequent 
were hypertension (1307/3700, 35.3%), chronic lung disease 
(719/3700, 19.4%), obesity (BMI ≥30; 597/3700, 16.1%), 
diabetes (505/3700, 13.6%), other CVD (442/3700, 11.9%) 
and CKD (258/3700, 7.0%). Among deceased patients, the 
proportion of those with comorbidities was higher, with 42.7% 
(165/386) having ≥3 comorbidities, namely, 54.9% (212/386) 
with hypertension, 35.8% (138/386) with chronic lung disease, 
24.6% (95/386) with diabetes, 32.1% (124/386) with other 
CVD and 19.9% (77/386) with CKD.
Treatments
At the time of COVID-19 diagnosis, 40.6% (1514/3729) of 
patients were treated only with csDMARDs, immunosuppres-
sants or combinations of these; 35.7% (1331/3729) received 
Figure 2 Patient flowchart. Some patients had diagnoses in multiple groups; as a result, the sum of patients in each group is greater than the total 
number of patients. (*) Patients belonging to more than one diagnosic group: IJD and CTD: N=78 (10 deaths); IJD and other: N=70 (12 deaths); CTD 
and other: N=50 (13 deaths); IJD and CTD and other: N=5 (2 deaths). (§) Patients belonging to more than one diagnosic group: IJD and CTD: N=77 
(10 deaths); IJD and other: N=70 (12 deaths); CTD and other: N=49 (12 deaths); IJD and CTD and other: N=5 (2 deaths). (#) Patients belonging to 
more than one diagnosic group: IJD and CTD: N=59 (7 deaths). (**) Non- typical DMARDs for IJD and RA: immunosuppressants and belimumab; non- 
typical DMARDs for RA: IL-17/IL-23/IL-12+23 inhibitors. (***) Non- typical DMARDs for CTD: abatacept, IL-17/IL-23/IL-12+23 inhibitors, sulfasalazine, 
leflunomide and tsDMARDs. b/tsDMARDs, biological/targeted synthetic disease- modifying antirheumatic drugs; CTD, connective tissue disease/
vasculitis; DMARDs, disease- modifying anti- rheumatic drugs; IJD, inflammatory joint disease; IL, interleukin; RA, rheumatoid arthritis.
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Table 1 Patient demographic and clinical characteristics
Parameter Not deceased Deceased Total
N 3339 390 3729
General       
Age (years) 55.5 (15.2) 69.7 (14.6) 57.0 (15.7)
  ≤30 197 (5.9) 9 (2.3) 206 (5.5)
  31–50 1012 (30.3) 31 (7.9) 1043 (28)
  51–65 1255 (37.6) 82 (21) 1337 (35.9)
  66–75 536 (16.1) 109 (27.9) 645 (17.3)
  >75 339 (10.2) 159 (40.8) 498 (13.4)
Male sex 1031 (30.9) 164 (42.1) 1195 (32)









Regions       
  African region 14 (0.4) 2 (0.5) 16 (0.4)
  Eastern Mediterranean 
region
83 (2.5) 11 (2.8) 94 (2.5)
  European region 2040 (61.1) 275 (70.5) 2315 (62.1)
  North American region 1024 (30.7) 81 (20.8) 1105 (29.6)
  South American region 112 (3.4) 10 (2.6) 122 (3.3)
  South- East Asian region 11 (0.3) 0 11 (0.3)
  Western Pacific region 55 (1.6) 11 (2.8) 66 (1.8)
Inflammatory joint 
diseases
      
Rheumatoid arthritis 1224 (36.7) 170 (43.6) 1394 (37.4)
Spondyloarthritis 416 (12.5) 15 (3.8) 431 (11.6)
Psoriatic arthritis 420 (12.6) 20 (5.1) 440 (11.8)
Juvenile idiopathic arthritis 
(poly, oligo, not systemic)
21 (0.6) 4 (1) 25 (0.7)
Other inflammatory arthritis 90 (2.7) 8 (2.1) 98 (2.6)
Total Inflammatory joint 
diseases
2158 (64.6) 215 (55.1) 2373 (63.6)
Connective tissue 
diseases/Vasculitis
      
Systemic lupus 
erythematosus
355 (10.6) 36 (9.2) 391 (10.5)
Connective tissue diseases 
(other than SLE)
473 (14.2) 60 (15.4) 533 (14.3)
Vasculitis 258 (7.7) 68 (17.4) 326 (8.7)
Total CTD 1035 (31) 158 (40.5) 1193 (32.0)
Other RMDs       







Remission 799 (32.4) 94 (32) 893 (32.4)
Minimal/low disease activity 1202 (48.8) 107 (36.4) 1309 (47.5)
Moderate disease activity 388 (15.7) 60 (20.4) 448 (16.2)
Severe/high disease activity 75 (3) 33 (11.2) 108 (3.9)

























Hypertension 1095 (33) 212 (54.9) 1307 (35.3)
Cardiovascular disease 318 (9.6) 124 (32.1) 442 (11.9)
Cerebrovascular disease 89 (2.7) 20 (5.2) 109 (2.9)
Chronic lung disease 581 (17.5) 138 (35.8) 719 (19.4)
Chronic kidney disease 181 (5.5) 77 (19.9) 258 (7)
Obesity (BMI ≥30) 539 (16.3) 58 (15) 597 (16.1)
Morbid obesity (BMI ≥40) 106 (3.2) 16 (4.1) 122 (3.3)
Diabetes 410 (12.4) 95 (24.6) 505 (13.6)
Cancer 165 (5) 49 (12.7) 214 (5.8)
Continued
Parameter Not deceased Deceased Total
Other comorbidities 771 (23.3) 126 (32.6) 897 (24.2)
Number of comorbities 1.3 (1.3) 2.5 (1.6) 1.4 (1.3)
  No comorbidity 1090 (32.9) 28 (7.3) 1118 (30.2)
  One comorbidity 1032 (31.1) 83 (21.5) 1115 (30.1)
  Two comorbidities 597 (18) 110 (28.5) 707 (19.1)
  ≥3 comorbidites 595 (18) 165 (42.7) 760 (20.5)
DMARD therapies       
csDMARDs monotherapy 592 (17.7) 59 (15.1) 651 (17.5)
csDMARDs combination 
therapy
692 (20.7) 61 (15.6) 753 (20.2)
  Methotrexate 
monotherapy
531 (15.9) 47 (12.1) 578 (15.5)
  Methotrexate combination 
therapy
607 (18.2) 52 (13.3) 659 (17.7)
  Leflunomide monotherapy 61 (1.8) 12 (3.1) 73 (2)
  Leflunomide combination 
therapy
120 (3.6) 10 (2.6) 130 (3.5)
  Sulfasalazine 
monotherapy
51 (1.5) 16 (4.1) 67 (1.8)
  Sulfasalazine combination 
therapy
129 (3.9) 26 (6.7) 155 (4.2)
  Antimalarial monotherapy 287 (8.6) 17 (4.4) 304 (8.2)
  Antimalarial combination 
therapy
322 (9.6) 39 (10) 361 (9.7)
Immunosuppressants 
monotherapy
149 (4.5) 26 (6.7) 175 (4.7)
Immunosuppressants 
combination therapy
147 (4.4) 21 (5.4) 168 (4.5)
  Mycophenolate mofetil 
monotherapy
68 (2) 14 (3.6) 82 (2.2)
  Mycophenolate mofetil 
combination therapy
81 (2.4) 15 (3.8) 96 (2.6)
  Azathioprine monotherapy 63 (1.9) 7 (1.8) 70 (1.9)
  Azathioprine combination 
therapy
51 (1.5) 3 (0.8) 54 (1.4)
  Cyclophosphamide 
monotherapy
10 (0.3) 3 (0.8) 13 (0.3)
  Cyclophosphamide 
combination therapy
5 (0.1) 5 (1.3) 10 (0.3)
  Tacrolimus monotherapy 5 (0.1) 2 (0.5) 7 (0.2)
  Tacrolimus combination 
therapy
11 (0.3) 0 11 (0.3)
  Ciclosporin monotherapy 3 (0.1) 0 3 (0.1)
  Ciclosporin combination 
therapy
11 (0.3) 1 (0.3) 12 (0.3)
bDMARDs monotherapy 675 (20.2) 48 (12.3) 723 (19.4)
bDMARDs combination 
therapy
562 (16.8) 46 (11.8) 608 (16.3)
TNF inhibitors monotherapy 434 (13) 13 (3.3) 447 (12)
TNF inhibitors combination 
therapy
340 (10.2) 17 (4.4) 357 (9.6)
Abatacept monotherapy 28 (0.8) 4 (1) 32 (0.9)
Abatacept combination 
therapy
46 (1.4) 5 (1.3) 51 (1.4)
B- cell- targeted bDMARDs 
monotherapy
71 (2.1) 25 (6.4) 96 (2.6)
B- cell- targeted bDMARDs 
combination therapy
106 (3.2) 18 (4.6) 124 (3.3)
  Rituximab monotherapy 66 (2) 25 (6.4) 91 (2.4)
  Rituximab combination 
therapy
85 (2.5) 17 (4.4) 102 (2.7)
  Belimumab monotherapy 5 (0.1) 0 5 (0.1)
  Belimumab combination 
therapy
22 (0.7) 1 (0.3) 23 (0.6)
IL-6 inhibitors monotherapy 51 (1.5) 3 (0.8) 54 (1.4)
IL-6 inhibitors combination 
therapy
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bDMARDs and 3.9% (147/3729) received tsDMARDs. One- 
fifth (739/3729, 19.8%) were not receiving any DMARD/
immunosuppressive treatment (except glucocorticoids), and 
this proportion was higher among deceased patients (124/390, 
31.8%).
Among the patients not receiving any DMARD/immunosup-
pressive treatment, 39.8% (290/729) received glucocorticoids, 
9.8% (70/712) with a prednisolone- equivalent dosage of >10 
mg/day; the most frequent diagnostic categories being other 
non- specified rheumatic diseases (173/739, 23.4%), vasculitis 
(161/739, 21.8%), CTD other than SLE (156/739, 21.1%) and 
RA (110/739, 14.9%).
Country-specific differences
The majority of cases (2993/3729, 80.3%) were reported from 
six countries with considerable differences in reported percent-
ages of death (online supplemental table 2). Overall, 10.5% 
(390/3729) of patients died, with highest proportions in the UK 
(91/435, 20.9%) and Italy (53/315, 16.8%). Death was reported 
in lower proportions in the USA (70/1005, 7.0%), Germany 
(15/198, 7.6%), France (62/793, 7.8%) and Spain (21/247, 
8.5%). Other major differences between the countries were 
the distribution of rheumatic diseases and the distribution and 
frequency of comorbidities.
Factors associated with death
In multivariable analyses (table 2, figure 3), patients between 66 
and 75 years of age were more likely to have died (OR 3.00, 
95% CI 2.13 to 4.22) than those ≤65 years. The association was 
even more pronounced in patients over 75 years (6.18, 4.47 to 
8.53; vs ≤65 years). Male sex was also associated with higher 
odds of death (1.46, 1.11 to 1.91). Current or former smoking 
was only associated with death in the RA subgroup (1.45, 1.02 
to 2.04).
Other factors associated with death included chronic lung 
disease (1.68, 1.26 to 2.25) and CVD combined with hyperten-
sion (1.89, 1.31 to 2.73), whereas hypertension or CVD alone 
did not show a significant association. CKD was significantly 
associated with death in patients with CTD or vasculitis (2.30, 
1.37 to 3.88) but not in other disease subgroups.
Across all diagnostic groups, treatments with leflunomide, 
antimalarials, TNF inhibitors, abatacept, belimumab, IL-6 inhib-
itors, IL-17/IL-23/IL-12+23 inhibitors and tsDMARDs were not 
associated with death, as compared with methotrexate mono-
therapy. In the overall model, not receiving DMARD treatment 
was associated with death (2.11, 1.48 to 3.01) compared with 
methotrexate monotherapy. This was also seen in the IJD, RA 
and CTD subgroups.
Compared with methotrexate monotherapy, treatments asso-
ciated with a higher odds of death were rituximab (4.04, 2.32 
to 7.03, in the overall model; 5.42, 2.77 to 10.61, in the IJD 
subgroup; 4.99, 2.43 to 10.26, in the RA subgroup; 3.72, 1.21 
to 11.48, in the CTD/vasculitis subgroup), sulfasalazine (3.60, 
1.66 to 7.78, in the overall model and consistent across all 
subgroups) and immunosuppressants (azathioprine, cyclophos-
phamide, ciclosporin, mycophenolate or tacrolimus: 2.22, 1.43 
to 3.46, in the overall model; 2.44, 1.06 to 5.65, in the CTD/
vasculitis subgroup; not applicable to other subgroups).
An additional analysis indicated that the association of sulfas-
alazine with an increased odds for death was mainly driven by 
the larger group of sulfasalazine monotherapy and persisted even 
when sulfasalazine combination treatment (plus either antima-
larials, leflunomide or methotrexate) was considered separately 
(data not shown).
Treatment with higher dosages of glucocorticoids (>10 mg/
day prednisolone- equivalent dose vs no use) was also found to 
be associated with death (1.69, 1.18 to 2.41), particularly in the 
CTD/vasculitis subgroup (1.93, 1.11 to 3.36).
Higher disease activity at COVID-19 diagnosis was consis-
tently associated with death across all disease groups. Patients 
with high/moderate/severe disease activity had higher odds 
of death (1.87, 1.27 to 2.77) than patients with low disease 
activity or in remission (overall model and consistent across all 
subgroups).
Sensitivity analyses
Results were largely consistent in our sensitivity analyses (online 
supplemental tables 4–9). In the complete case analysis (online 
supplemental table 5), the association between sulfasalazine and 
death was no longer statistically significant. In stratified analyses 
(online supplemental tables 10–16), sulfasalazine use was not 
associated with death among patients that never smoked, with 
the OR among ever smokers being almost threefold than among 
non- smokers (online supplemental table 12).
DISCUSSION
With global cooperation, the C19- GRA physician- reported 
registry is the largest collection to date of patients with rheumatic 
Parameter Not deceased Deceased Total
IL-1 inhibitors monotherapy 10 (0.3) 2 (0.5) 12 (0.3)
IL-1 inhibitors combination 
therapy
4 (0.1) 4 (1) 8 (0.2)
IL-17, IL-23, IL-12/23 
inhibitors monotherapy
79 (2.4) 1 (0.3) 80 (2.1)
IL-17, IL-23, IL-12/23 
inhibitors combination 
therapy
36 (1.1) 0 36 (1)
tsDMARDs monotherapy 61 (1.8) 5 (1.3) 66 (1.8)
tsDMARDs (*) combination 
therapy
71 (2.1) 10 (2.6) 81 (2.2)
  JAK inhibitors 
monotherapy
54 (1.6) 4 (1) 58 (1.6)
  JAK inhibitors 
combination therapy
67 (2) 9 (2.3) 76 (2)
  Apremilast monotherapy 7 (0.2) 1 (0.3) 8 (0.2)
  Apremilast combination 
therapy
3 (0.1) 1 (0.3) 4 (0.1)
No DMARD therapies 615 (18.4) 124 (31.8) 739 (19.8)
Further therapies       








































Data are N (column %) for categorical variables or mean (SD) for continuous variables. The table 
includes all patients with a non- missing outcome and non- missing values for age, sex and disease- 
modifying anti- rheumatic drugs (DMARDs) (101 patients excluded). Data refer to patients with 
non- missing values for the respective variable; total N for patients with non- missing values is given 
in parentheses for variables with missing values; the total number of missing values is also given in 
parenthesis, for the applicable variables. (*) Includes one patient on a study medication (Lenabasum). 
(#) Includes patients with a missing glucocorticoid dosage.
bDMARD, biological disease- modifying antirheumatic drug; BMI, body mass index; csDMARD, 
conventional synthetic disease- modifying antirheumatic drug; CTD, connective tissue diseases; DMARD, 
disease- modifying antirheumatic drug; IL, interleukin; JAK, Janus kinase; JIA, juvenile idiopathic 
arthritis; N, number; NSAID, non- steroidal anti- inflammatory drugs; SLE, systemic lupus erythematosus; 
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diseases and COVID-19. We found that moderate/high disease 
activity was significantly associated with COVID-19- related 
death, confirming recent recommendations regarding the impor-
tance of disease control in rheumatic diseases in the COVID-19 
era.1 Other factors associated with death were older age, male 
sex and the presence of comorbidities, which is consistent with 
reports from the general population.8 Overall, compared with 
methotrexate monotherapy, most DMARDs were not associated 
with higher odds of death, although rituximab and sulfasala-
zine were notable exceptions. Prednisolone- equivalent dosages 
>10 mg/day and other immunosuppressive drugs (as opposed 
to immunomodulatory DMARDs) were also associated with 
COVID-19- related death.
In this cohort of patients with underlying rheumatic diseases, 
the COVID-19- related death rate was 10.5%, clearly higher 
than that reported in the general population in most countries. 
However, this study was not designed to calculate a precise point 
estimate for mortality. Reporting biases and population- related 
factors, including COVID-19 testing rates, could explain this 
figure and, importantly, it should not be taken as an estimate of 
the overall death rate among patients with rheumatic diseases 
and COVID-19.
The association of rituximab with poorer COVID-19- related 
outcomes is a previously unreported finding outside of case 
reports. Rituximab binds to CD20 on the surface of B- cells, 
effectively depleting this cell type, and interferes with antibody 
development. Therefore, B- cell depletion could potentially 
compromise antiviral immunity, including the development of 
SARS- CoV-2 antibodies.19 With our data, it was not possible to 
determine the exact timing of infection following rituximab infu-
sion, although all patients were clinically judged by their rheu-
matologist to have been exposed to the immunological effects 
of the drug at the time of COVID-19 diagnosis. The association 
between rituximab and COVID-19- related death could have also 
been influenced by the typical coadministration of methylpred-
nisolone with rituximab.
A finding that merits further research is the higher odds 
of death found with sulfasalazine treatment. This asso-
ciation has also been reported in results from an interna-
tional registry of patients with inflammatory bowel disease 
and COVID-19, where sulfasalazine or 5- aminosalicylate 
(5- ASA) use was associated with severe COVID-19 (adjusted 
OR of 3.1 (1.3 to 7.7)).20 This finding is surprising as sulfas-
alazine is usually considered to have a low immunosuppres-
sive effect. Prior research supports an immune regulatory 
effect driven by sulfasalazine or its metabolite 5- ASA against 
other RNA viruses.21–24 However, causal interpretation of 
the association between sulfasalazine and COVID-19- related 
death should not be made. The perceived low immunosup-
pressive effect of sulfasalazine may have led rheumatologists 
to prescribe preferentially sulfasalazine over methotrexate 
in patients who were perceived to be at higher risk, for 
example, patients with pulmonary disease, smoking or recur-
rent chest infections. In an observational study like ours, this 
could lead to unmeasured confounding. A salient difference 
in sulfasalazine users in our study was a higher proportion 
of current or former smokers, compared with non- users. In 
the stratified analyses for chronic lung disease, the associa-
tion between death and sulfasalazine was significant in both 
subgroups with and without chronic lung disease, while in 
the stratified analyses for smoking, the association between 
death and sulfasalazine was limited to ever smokers, so the 
factor ‘smoking’ could potentially be an effect modifier. 
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merging of sulfasalazine combination therapy (with other 
csDMARDs) with sulfasalazine monotherapy; however, the 
increased odds for death persisted in the sulfasalazine mono-
therapy group and was not driven by the combination treat-
ment (data not shown).
Despite the large overall sample size, for some therapies 
(eg, IL-6 and IL-17/IL-23/IL-12+23 inhibitors) the number 
of users was low and no firm conclusions could be made. 
IL-6 inhibitors have been used to counteract the hyperin-
flammatory state produced by COVID-19, with mostly 
disappointing randomised trial results.25 26 Their efficacy 
is still being investigated in ongoing trials, but it is reas-
suring that they were not associated with COVID-19- related 
death in our analyses. Previous studies had shown an associ-
ation between TNF inhibitors and a decreased risk of sepsis 
and mortality in patients with RA after serious infection 
compared with csDMARDs.27 28 We could not confirm such 
an association after stratification by disease and adjust-
ment for disease activity. However, the data indicate that 
some associations may exist among patients diagnosed with 
IJD other than RA (a subgroup comprising predominantly 
patients with axial SpA and PsA), in whom male sex and 
diabetes mellitus were associated with a higher odds of 
death, and TNF inhibitor use was associated with a lower 
odds of death (univariable analysis, data not shown). Due to 
a small number of deceased patients in this subgroup with 
non- RA subtypes of IJD (n=37 deaths), these effects could 
not be assessed in a multivariable model and this should be 
investigated in the future when higher case numbers allow a 
more stable assessment.
This study has limitations. As a cross- sectional, case- 
reporting registry, it may be subject to selection bias if more 
Figure 3 Results of the main logistic regression analysis. Shown are multivariable- adjusted ORs for the outcome COVID-19- related death with 95% 
CIs, assessing the association with (A) general patient characteristics, (B) comorbidities, (C) rheumatic disease diagnoses (RMD) and (D) rheumatic 
disease medications. ORs are shown for four groups: all patients (black), patients with inflammatory joint disease (red), patients with rheumatoid 
arthritis (orange), and patients with a connective tissue disease or vasculitis (blue). For (C), only ORs for all patients are shown. The reference 
categories are as follows: (A) ≤65 years, females, never smoked, remission or low disease activity; (B) the non- presence of the specific comorbidities 
(for all effects); (C) rheumatoid arthritis (for all effects); (D) methotrexate monotherapy (for all effects except for glucocorticoids), no glucocorticoids 
(for glucocorticoid dosage groups). Patients receiving multiple csDMARDs or immunosuppressants (except glucocorticoids) were grouped according 
to the following hierarchy: immunosuppressants>sulfasalazine>antimalarials>leflunomide>methotrexate; patients receiving a b/tsDMARD were 
considered solely in the b/tsDMARD group; glucocorticoids were examined separately and categorised by prednisolone- equivalent dosage (1–10 mg/
day and >10 mg/day). bDMARD, biological disease- modifying anti- rheumatic drug; csDMARD, conventional synthetic disease- modifying antirheumatic 
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severe cases are more likely to come to the rheumatologists’ 
attention and therefore to be reported. There is an absence 
of a population- based comparator, and we are unable to 
make comparisons between those with and without COVID-
19. Moreover, we caution against interpreting our estimates 
causally. There is likely unmeasured confounding dependent 
on the particularities of health systems and case reporting 
differences. We tried to address this by limiting the research 
questions to those that could be answered with this dataset 
and by accounting for potential confounders in our analyses. 
The high number of variables compared with outcome events 
in the subgroup models may result in biased estimates.29 30 
However, the consistency between the main model and the 
sensitivity analyses (including using a lower number of vari-
ables) do not indicate an issue with overfitting.
In conclusion, people with rheumatic diseases with higher 
disease activity have higher odds of COVID-19- related 
death, highlighting the importance of disease control, pref-
erably by managing DMARDs effectively without increasing 
glucocorticoids. Future studies should address the observed 
association of rituximab and sulfasalazine with poor 
outcomes. Finally, as in the general population, older age, 
male sex and/or the presence of comorbidities increase the 
odds of COVID-19- related death.
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Supplementary table 1. Patient demographic and clinical characteristics stratified by rheumatic disease diagnostic subgroup 
 
 Inflammatory joint diseases Rheumatoid arthritis Connective tissue diseases and vasculitis 
Parameter Not deceased Deceased Total Not deceased Deceased Total Not deceased Deceased Total 
N 2158 215 2373 1224 170 1394 1035 158 1193 
          
General          
Age [years] 55.7 (14.3) 71.6 (11.7) 57.1 (14.8) 59.2 (13.9) 72.5 (11.1) 60.8 (14.3) 55.1 (16.3) 66.7 (17.4) 56.7 (16.9) 
    ≤ 30 years 103 (4.8) 1 (0.5) 104 (4.4) 37 (3) 1 (0.6) 38 (2.7) 73 (7.1) 8 (5.1) 81 (6.8) 
    31 – 50 years 637 (29.5) 9 (4.2) 646 (27.2) 264 (21.6) 5 (2.9) 269 (19.3) 337 (32.6) 20 (12.7) 357 (29.9) 
    51 – 65 years 878 (40.7) 45 (20.9) 923 (38.9) 514 (42) 34 (20) 548 (39.3) 334 (32.3) 35 (22.2) 369 (30.9) 
    66 – 75 years 359 (16.6) 72 (33.5) 431 (18.2) 262 (21.4) 56 (32.9) 318 (22.8) 155 (15) 35 (22.2) 190 (15.9) 
    > 75 years 181 (8.4) 88 (40.9) 269 (11.3) 147 (12) 74 (43.5) 221 (15.9) 136 (13.1) 60 (38) 196 (16.4) 




















Regions          
    African Region 10 (0.5) 1 (0.5) 11 (0.5) 7 (0.6) 1 (0.6) 8 (0.6) 2 (0.2) 1 (0.6) 3 (0.3) 
    Eastern Mediterranean Region 46 (2.1) 4 (1.9) 50 (2.1) 33 (2.7) 4 (2.4) 37 (2.7) 37 (3.6) 8 (5.1) 45 (3.8) 
    European Region 1405 (65.1) 157 (73) 1562 
(65.8) 
725 (59.2) 121 (71.2) 846 (60.7) 533 (51.5) 103 (65.2) 636 (53.3) 
    North American Region 595 (27.6) 44 (20.5) 639 (26.9) 392 (32) 38 (22.4) 430 (30.8) 397 (38.4) 35 (22.2) 432 (36.2) 
    South American Region 68 (3.2) 4 (1.9) 72 (3) 48 (3.9) 1 (0.6) 49 (3.5) 42 (4.1) 5 (3.2) 47 (3.9) 
    South-East Asian Region 8 (0.4) 0 8 (0.3) 3 (0.2) 0 3 (0.2) 2 (0.2) 0 2 (0.2) 
    Western Pacific Region 26 (1.2) 5 (2.3) 31 (1.3) 16 (1.3) 5 (2.9) 21 (1.5) 22 (2.1) 6 (3.8) 28 (2.3) 
          
Inflammatory joint diseases          
Rheumatoid arthritis 1224 (56.7) 170 (79.1) 1394 
(58.7) 
1224 (100) 170 (100) 1394 (100) 53 (5.1) 9 (5.7) 62 (5.2) 
Spondyloarthritis 416 (19.3) 15 (7) 431 (18.2) 1 (0.1) 0 1 (0.1) 2 (0.2) 0 2 (0.2) 
Psoriatic arthritis 420 (19.5) 20 (9.3) 440 (18.5) 1 (0.1) 1 (0.6) 2 (0.1) 8 (0.8) 0 8 (0.7) 
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JIA (poly, oligo, not systemic) 21 (1) 4 (1.9) 25 (1.1) 2 (0.2) 0 2 (0.1) 0 0 0 
Other inflammatory arthritis 90 (4.2) 8 (3.7) 98 (4.1) 3 (0.2) 0 3 (0.2) 7 (0.7) 1 (0.6) 8 (0.7) 
Total Inflammatory joint diseases 2158 (100) 215 (100) 2373 (100) 1224 (100) 170 (100) 1394 (100) 68 (6.6) 10 (6.3) 78 (6.5) 
Connective tissue diseases / Vasculitis          
SLE 20 (0.9) 3 (1.4) 23 (1) 18 (1.5) 3 (1.8) 21 (1.5) 355 (34.3) 36 (22.8) 391 (32.8) 
CTDs (other than SLE) 38 (1.8) 7 (3.3) 45 (1.9) 33 (2.7) 6 (3.5) 39 (2.8) 473 (45.7) 60 (38) 533 (44.7) 
Vasculitis 14 (0.6) 1 (0.5) 15 (0.6) 6 (0.5) 1 (0.6) 7 (0.5) 258 (24.9) 68 (43) 326 (27.3) 
Total CTD 68 (3.2) 10 (4.7) 78 (3.3) 53 (4.3) 9 (5.3) 62 (4.4) 1035 (100) 158 (100) 1193 (100) 
Other RMDs          
Total 58 (2.7) 12 (5.6) 70 (2.9) 30 (2.5) 6 (3.5) 36 (2.6) 37 (3.6) 13 (8.2) 50 (4.2) 
          
Disease activity N=1563 N=168 N=1731 N=943 N=131 N=1074 N=822 N=118 N=940 
Remission 488 (31.2) 54 (32.1) 542 (31.3) 291 (30.9) 40 (30.5) 331 (30.8) 256 (31.1) 32 (27.1) 288 (30.6) 
Minimal/low disease activity 771 (49.3) 65 (38.7) 836 (48.3) 464 (49.2) 51 (38.9) 515 (48) 421 (51.2) 38 (32.2) 459 (48.8) 
Moderate disease activity 264 (16.9) 38 (22.6) 302 (17.4) 161 (17.1) 30 (22.9) 191 (17.8) 115 (14) 25 (21.2) 140 (14.9) 
Severe/high disease activity 40 (2.6) 11 (6.5) 51 (2.9) 27 (2.9) 10 (7.6) 37 (3.4) 30 (3.6) 23 (19.5) 53 (5.6) 
          







































          
Comorbidities N=2143 N=214 N=2357 N=1215 N=169 N=1384 N=1026 N=155 N=1181 
Hypertension 658 (30.7) 116 (54.2) 774 (32.8) 423 (34.8) 90 (53.3) 513 (37.1) 385 (37.5) 87 (56.1) 472 (40) 
Cardiovascular disease 183 (8.5) 71 (33.2) 254 (10.8) 126 (10.4) 54 (32) 180 (13) 121 (11.8) 43 (27.7) 164 (13.9) 
Cerebrovascular disease 49 (2.3) 10 (4.7) 59 (2.5) 38 (3.1) 8 (4.7) 46 (3.3) 34 (3.3) 8 (5.2) 42 (3.6) 
Chronic lung disease 332 (15.5) 78 (36.4) 410 (17.4) 231 (19) 65 (38.5) 296 (21.4) 234 (22.8) 58 (37.4) 292 (24.7) 
Chronic kidney disease 83 (3.9) 27 (12.6) 110 (4.7) 61 (5) 21 (12.4) 82 (5.9) 85 (8.3) 42 (27.1) 127 (10.8) 
Obesity (BMI ≥ 30) 370 (17.3) 38 (17.8) 408 (17.3) 205 (16.9) 27 (16) 232 (16.8) 155 (15.1) 19 (12.3) 174 (14.7) 
Morbid obesity (BMI ≥ 40) 51 (2.4) 8 (3.7) 59 (2.5) 28 (2.3) 8 (4.7) 36 (2.6) 50 (4.9) 8 (5.2) 58 (4.9) 
Diabetes 260 (12.1) 55 (25.7) 315 (13.4) 176 (14.5) 39 (23.1) 215 (15.5) 126 (12.3) 36 (23.2) 162 (13.7) 
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Cancer 98 (4.6) 23 (10.7) 121 (5.1) 68 (5.6) 18 (10.7) 86 (6.2) 61 (5.9) 20 (12.9) 81 (6.9) 
Other comorbidities 509 (23.8) 73 (34.1) 582 (24.7) 216 (17.8) 48 (28.4) 264 (19.1) 230 (22.4) 45 (29.0) 275 (23.3) 
Number of comorbities 1.2 (1.3) 2.5 (1.7) 1.4 (1.4) 1.3 (1.3) 2.3 (1.6) 1.4 (1.4) 1.5 (1.4) 2.5 (1.5) 1.6 (1.4) 
    No comorbidity 770 (35.9) 18 (8.4) 788 (33.4) 397 (32.7) 16 (9.5) 413 (29.8) 267 (26) 10 (6.5) 277 (23.5) 
    One comorbidity 639 (29.8) 50 (23.4) 689 (29.2) 374 (30.8) 39 (23.1) 413 (29.8) 357 (34.8) 31 (20) 388 (32.9) 
    Two comorbidities 390 (18.2) 63 (29.4) 453 (19.2) 238 (19.6) 52 (30.8) 290 (21) 182 (17.7) 43 (27.7) 225 (19.1) 
    ≥ 3 comorbidites 344 (16.1) 83 (38.8) 427 (18.1) 206 (17) 62 (36.7) 268 (19.4) 220 (21.4) 71 (45.8) 291 (24.6) 
          
DMARD therapies          
csDMARDs monotherapy 487 (22.6) 51 (23.7) 538 (22.7) 351 (28.7) 43 (25.3) 394 (28.3) 91 (8.8) 10 (6.3) 101 (8.5) 
csDMARDs combination therapy 611 (28.3) 53 (24.7) 664 (28) 440 (35.9) 51 (30) 491 (35.2) 92 (8.9) 12 (7.6) 104 (8.7) 
    Methotrexate monotherapy 430 (19.9) 41 (19.1) 471 (19.8) 306 (25) 34 (20) 340 (24.4) 88 (8.5) 6 (3.8) 94 (7.9) 
    Methotrexate combination therapy 531 (24.6) 45 (20.9) 576 (24.3) 372 (30.4) 44 (25.9) 416 (29.8) 87 (8.4) 9 (5.7) 96 (8) 
    Leflunomide monotherapy 57 (2.6) 10 (4.7) 67 (2.8) 45 (3.7) 9 (5.3) 54 (3.9) 3 (0.3) 4 (2.5) 7 (0.6) 
    Leflunomide combination therapy 114 (5.3) 9 (4.2) 123 (5.2) 98 (8) 8 (4.7) 106 (7.6) 7 (0.7) 3 (1.9) 10 (0.8) 
    Sulfasalazine monotherapy 48 (2.2) 16 (7.4) 64 (2.7) 22 (1.8) 8 (4.7) 30 (2.2) 3 (0.3) 1 (0.6) 4 (0.3) 
    Sulfasalazine combination therapy 124 (5.7) 24 (11.2) 148 (6.2) 76 (6.2) 20 (11.8) 96 (6.9) 7 (0.7) 2 (1.3) 9 (0.8) 
    Antimalarial monotherapy 74 (3.4) 8 (3.7) 82 (3.5) 56 (4.6) 8 (4.7) 64 (4.6) 212 (20.5) 9 (5.7) 221 (18.5) 
    Antimalarial combination therapy 175 (8.1) 23 (10.7) 198 (8.3) 156 (12.7) 23 (13.5) 179 (12.8) 169 (16.3) 17 (10.8) 186 (15.6) 
Immunosuppressants monotherapy 9 (0.4) 3 (1.4) 12 (0.5) 7 (0.6) 3 (1.8) 10 (0.7) 132 (12.8) 21 (13.3) 153 (12.8) 
Immunosuppressants combination 
therapy 
20 (0.9) 1 (0.5) 21 (0.9) 16 (1.3)   16 (1.1) 127 (12.3) 18 (11.4) 145 (12.2) 
    Mycophenolate mofetil monotherapy 3 (0.1) 1 (0.5) 4 (0.2) 2 (0.2) 1 (0.6) 3 (0.2) 64 (6.2) 13 (8.2) 77 (6.5) 
    Mycophenolate mofetil combination 
therapy 
3 (0.1) 0 3 (0.1) 3 (0.2) 0 3 (0.2) 77 (7.4) 14 (8.9) 91 (7.6) 
    Azathioprine monotherapy 4 (0.2) 1 (0.5) 5 (0.2) 3 (0.2) 1 (0.6) 4 (0.3) 54 (5.2) 4 (2.5) 58 (4.9) 
    Azathioprine combi 12 (0.6) 1 (0.5) 13 (0.5) 9 (0.7) 0 9 (0.6) 39 (3.8) 2 (1.3) 41 (3.4) 
    Cyclophosphamide monotherapy 0 0 0 0 0 0 9 (0.9) 3 (1.9) 12 (1) 
    Cyclophosphamide combination 
therapy 
0 0 0 0 0 0 5 (0.5) 4 (2.5) 9 (0.8) 
    Tacrolimus monotherapy 0 1 (0.5) 1 (0) 0 1 (0.6) 1 (0.1) 4 (0.4) 1 (0.6) 5 (0.4) 
    Tacrolimus combination therapy 2 (0.1) 0 2 (0.1) 1 (0.1) 0 1 (0.1) 8 (0.8) 0 8 (0.7) 
    Cyclosporin monotherapy 2 (0.1) 0 2 (0.1) 2 (0.2) 0 2 (0.1) 1 (0.1) 0 1 (0.1) 
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    Cyclosporin combination therapy 4 (0.2) 0 4 (0.2) 4 (0.3) 0 4 (0.3) 8 (0.8) 1 (0.6) 9 (0.8) 
bDMARDs monotherapy 581 (26.9) 29 (13.5) 610 (25.7) 163 (13.3) 19 (11.2) 182 (13.1) 81 ( 7.8) 18 (11.4) 99 (8.3) 
bDMARD combination therapy 478 (22.2) 31 (14.4) 509 (21.5) 308 (25.2) 29 (17.1) 337 (24.2) 91 (8.8) 15 (9.5) 106 (8.9) 
TNF inhibitors monotherapy 417 (19.3) 12 (5.6) 429 (18.1) 88 (7.2) 4 (2.4) 92 (6.6) 15 (1.4) 1 (0.6) 16 (1.3) 
TNF inhibitors combination therapy 322 (14.9) 14 (6.5) 336 (14.2) 189 (15.4) 12 (7.1) 201 (14.4) 20 (1.9) 3 (1.9) 23 (1.9) 
Abatacept monotherapy 25 (1.2) 4 (1.9) 29 (1.2) 20 (1.6) 4 (2.4) 24 (1.7) 2 (0.2) 0 2 (0.2) 
Abatacept combination therapy 43 (2) 5 (2.3) 48 (2) 41 (3.3) 5 (2.9) 46 (3.3) 6 (0.6) 0 6 (0.5) 
B-cell-targeted  bDMARDs monotherapy 22 (1) 11 (5.1) 33 (1.4) 20 (1.6) 10 (5.9) 30 (2.2) 45 (4.3) 15 (9.5) 60 (5) 
B-cell-targeted  bDMARDs combination 
therapy 
49 (2.3) 11 (5.1) 60 (2.5) 48 (3.9) 11 (6.5) 59 (4.2) 62 (6) 8 (5.1) 70 (5.9) 
    Rituximab monotherapy 22 (1) 11 (5.1) 33 (1.4) 20 (1.6) 10 (5.9) 30 (2.2) 40 (3.9) 15 (9.5) 55 (4.6) 
    Rituximab combi 47 (2.2) 11 (5.1) 58 (2.4) 46 (3.8) 11 (6.5) 57 (4.1) 42 (4.1) 7 (4.4) 49 (4.1) 
    Belimumab monotherapy 0 0 0 0 0 0 5 (0.5) 0 5 (0.4) 
    Belimumab combination therapy 2 (0.1) 0 2 (0.1) 2 (0.2) 0 2 (0.1) 21 (2) 1 (0.6) 22 (1.8) 
IL-6 inhibitors monotherapy 36 (1.7) 1 (0.5) 37 (1.6) 33 (2.7) 1 (0.6) 34 (2.4) 18 (1.7) 2 (1.3) 20 (1.7) 
IL-6 inhibitors combination therapy 31 (1.4) 0 31 (1.3) 29 (2.4) 0 29 (2.1) 1 (0.1) 2 (1.3) 3 (0.3) 
IL-1 inhibitors monotherapy 1 (0) 0 1 (0) 0 0 0 1 (0.1) 0 1 (0.1) 
IL-1 inhibitors combination therapy 3 (0.1) 1 (0.5) 4 (0.2) 3 (0.2) 1 (0.6) 4 (0.3) 1 (0.1) 2 (1.3) 3 (0.3) 
IL-17, Il-23, Il-12/23 inhibitors 
monotherapy 
78 (3.6) 1 (0.5) 79 (3.3) 1 (0.1) 0 1 (0.1) 
0 0 0 
IL-17, Il-23, Il-12/23 inhibitors 
combination therapy 
34 (1.6) 0 34 (1.4) 1 (0.1) 0 1 (0.1) 1 (0.1) 0 1 (0.1) 
tsDMARDs monotherapy 61 (2.8) 5 (2.3) 66 (2.8) 47 (3.8) 4 (2.4) 51 (3.7) 0 0 0 
tsDMARDs (*) combination therapy 68 (3.2) 10 (4.7) 78 (3.3) 59 (4.8) 9 (5.3) 68 (4.9) 6 (0.6) 2 (1.3) 8 (0.7) 
    JAK inhibitors monotherapy 54 (2.5) 4 (1.9) 58 (2.4) 47 (3.8) 4 (2.4) 51 (3.7) 0 0 0 
    JAK inhibitors combination therapy 65 (3) 9 (4.2) 74 (3.1) 59 (4.8) 9 (5.3) 68 (4.9) 5 (0.5) 2 (1.3) 7 (0.6) 
    Apremilast monotherapy 7 (0.3) 1 (0.5) 8 (0.3) 0 0 0 0 0 0 
    Apremilast combination therapy 3 (0.1) 1 (0.5) 4 (0.2) 0 0 0 0 0 0 
No DMARD therapies 201 (9.3) 38 (17.7) 239 (10.1) 85 (6.9) 25 (14.7) 110 (7.9) 286 (27.6) 67 (42.4) 353 (29.6) 
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Data are N (column %) for categorical variables or mean (SD) for continuous variables. Table includes all patients with a non-missing outcome and non-missing values for age, sex 
and disease modifying anti-rheumatic drugs (DMARDs) (101 patients excluded). Data refers to patients with non-missing values for the respective variable, total N for patients with 
non-missing values is given in parentheses for variables with missing values. (*) Includes one patient on a study medication (Lenabasum). (#) Includes patients with a missing 
glucocorticoid dose.  
 
bDMARD, biologic disease modifying antirheumatic drugs; BMI, body mass index; csDMARD, conventional synthetic disease modifying antirheumatic drugs; CTD, connective tissue 
diseases; DMARD, disease modifying antirheumatic drugs; IL, interleukin; JAK, Janus kinase; JIA, juvenile idiopathic arthritis; N, number; NSAID, non-steroidal anti-inflammatory 
drugs; SLE, systemic lupus erythematosus; TNF; tumour necrosis factor; tsDMARD, targeted synthetic disease modifying antirheumatic drugs. 
BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
Supplemental material placed on this supplemental material which has been supplied by the author(s) Ann Rheum Dis





Supplementary table 2. Patient demographic and clinical characteristics stratified by country (six countries with the highest number 
of reported cases) 
 
Parameter USA France UK Italy Spain Germany Total 
N 1005 793 435 315 247 198 2993 
        
General        
Age [years] 55.2 (15.1) 56.2 (16.3) 61.2 (16.4) 61.9 (13.7) 59.7 (15.7) 58.2 (13.8) 57.6 (15.6) 
 < 30 years 66 (6.6) 39 (4.9) 16 (3.7) 6 (1.9) 10 (4) 6 (3) 143 (4.8) 
 30 – 49 years 300 (29.9) 268 (33.8) 97 (22.3) 58 (18.4) 56 (22.7) 48 (24.2) 268 (33.8) 
 50 – 65 years 390 (38.8) 248 (31.3) 131 (30.1) 107 (34) 92 (37.2) 93 (47) 248 (31.3) 
                66 - 75 years 146 (14.5) 128 (16.1) 92 (21.1) 93 (29.5) 43 (17.4) 26 (13.1) 528 (17.6) 
 > 75 years 103 (10.2) 110 (13.9) 99 (22.8) 51 (16.2) 46 (18.6) 25 (12.6) 434 (14.5) 
















        
Inflammatory joint diseases        
Rheumatoid arthritis 388 (38.6) 247 (31.2) 187 (43.0) 105 (33.3) 88 (35.6) 99 (50.0) 1114 (37.2) 
Spondyloarthritis 47 (4.7) 193 (24.3) 29 (6.7) 24 (7.6) 32 (13) 19 (9.6) 344 (11.5) 
Psoriatic arthritis 101 (10) 74 (9.3) 61 (14) 64 (20.3) 31 (12.6) 32 (16.2) 363 (12.1) 
JIA (poly, oligo, not systemic) 7 (0.7) 2 (0.3) 2 (0.5) 2 (0.6) 3 (1.2) 0 16 (0.5) 
Other inflammatory arthritis 41 (4.1) 15 (1.9) 28 (6.4) 3 (1) 3 (1.2) 0 90 (3) 
Total IJD 577 (57.4) 531 (67) 305 (70.1) 198 (62.9) 157 (63.6) 150 (75.8) 1918 (64.1) 
Connective tissue diseases / 
Vasculitis 




Systemic lupus erythematosus 167 (16.6) 50 (6.3) 28 (6.4) 18 (5.7) 27 (10.9) 9 (4.5) 299 (10) 
CTDs (other than SLE) 186 (18.5) 90 (11.3) 38 (8.7) 53 (16.8) 44 (17.8) 19 (9.6) 430 (14.4) 
Vasculitis 67 (6.7) 71 (9) 51 (11.7) 44 (14) 22 (8.9) 18 (9.1) 273 (9.1) 
Total CTD 394 (39.2) 211 (26.6) 111 (25.5) 114 (36.2) 85 (34.4) 43 (21.7) 958 (32) 
Other rheumatic diseases        
Total 132 (13.1) 52 (6.6) 53 (12.2) 8 (2.5) 20 (8.1) 13 (6.6) 278 (9.3) 
        
Disease activity (DA) N=950  N=364 N=315 242 N=181 N=2052 
 Remission 211 (22.2) N/A 109 (29.9) 93 (29.5) 113 (46.7) 102 (56.4) 628 (30.6) 
 Minimal/low DA 521 (54.8) N/A 172 (47.3) 160 (50.8) 108 (44.6) 53 (29.3) 1014 (49.4) 
 Moderate DA 185 (19.5) N/A 69 (19) 53 (16.8) 17 (7) 19 (10.5) 343 (16.7) 
 Severe/high DA 33 (3.5) N/A 14 (3.8) 9 (2.9) 4 (1.7) 7 (3.9) 67 (3.3) 
        
Other outcomes        
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Comorbidities N=1000 N=791 N=434 N=300 N=247 N=192 N=2964 
Hypertension 399 (39.9) 220 (27.8) 140 (32.3) 147 (49) 103 (41.7) 72 (36.4) 1081 (36.4) 
Cardiovascular disease 112 (11.2) 76 (9.6) 72 (16.6) 72 (24) 18 (7.3) 27 (13.6) 377 (12.7) 
Cerebrovascular disease 27 (2.7) 28 (3.5) 17 (3.9) 14 (4.7) 6 (2.4) 0 92 (3.1) 
Chronic lung disease 231 (23.1) 113 (14.3) 108 (24.9) 75 (25) 54 (21.9) 32 (16.2) 613 (20.6) 
Chronic kidney disease 85 (8.5) 46 (5.8) 28 (6.5) 27 (9) 11 (4.5) 15 (7.6) 212 (7.1) 
Obesity (BMI ≥ 30) 244 (24.4) 138 (17.4) 39 (9) 47 (15.7) 31 (12.6) 30 (15.2) 529 (17.8) 
Morbid obesity (BMI ≥ 40) 87 (8.7) 0 11 (2.5) 7 (2.3) 2 (0.8) 7 (3.5) 114 (3.8) 
Diabetes 171 (17.1) 74 (9.4) 73 (16.8) 42 (14) 31 (12.6) 17 (8.6) 408 (13.7) 
Cancer 68 (6.8) 36 (4.6) 19 (4.4) 34 (11.3) 23 (9.3) 7 (3.5) 187 (6.3) 
Other comorbidities 213 (21.3) 159 (20.1) 151 (34.8) 145 (48.3) 67 (27.1) 53 (27.6) 788 (36.2) 
Number of comorbities 1.7 (1.5) 1.1 (1.1) 1.6 (1.4) 2.3 (1.8) 1.5 (1.4) 1.3 (1.3) 1.5 (1.5) 
No comorbidity 250 (25) 277 (35) 105 (24.2) 44 (14.7) 70 (28.3) 67 (33.8) 813 (27.4) 
One comorbidity 275 (27.5) 276 (34.9) 136 (31.3) 79 (26.3) 77 (31.2) 58 (29.3) 901 (30.3) 
Two comorbidities 211 (21.1) 143 (18.1) 98 (22.6) 57 (19) 51 (20.6) 39 (19.7) 599 (20.2) 
≥ 3 comorbidites 264 (26.4) 95 (12) 95 (21.9) 120 (40) 49 (19.8) 34 (17.2) 657 (22.1) 
        
DMARD therapies        
csDMARDs mono 106 (10.5) 159 (20.1) 91 (20.9) 66 (21) 51 (20.6) 52 (26.3) 525 (17.5) 
csDMARDs combi 208 (20.7) 164 (20.7) 84 (19.3) 58 (18.4) 40 (16.2) 33 (16.7) 587 (19.6) 
 Methotrexate mono 88 (8.8) 151 (19) 83 (19.1) 55 (17.5) 45 (18.2) 47 (23.7) 469 (15.7) 
 Methotrexate combi 174 (17.3) 142 (17.9) 78 (17.9) 52 (16.5) 36 (14.6) 33 (16.7) 515 (17.2) 
 Leflunomide mono 18 (1.8) 8 (1) 8 (1.8) 11 (3.5) 6 (2.4) 5 (2.5) 56 (1.9) 
 Leflunomide combi 40 (4) 22 (2.8) 11 (2.5) 6 (1.9) 7 (2.8) 3 (1.5) 89 (3) 
Sulfasalazine mono 7 (0.7) 3 (0.4) 21 (4.8) 4 (1.3) 6 (2.4) 7 (3.5) 48 (1.6) 
Sulfasalazine combi 33 (3.3) 6 (0.8) 47 (10.8) 10 (3.2) 10 (4) 2 (1) 108 (3.6) 
Antimalarial mono 120 (11.9) 32 (4) 20 (4.6) 28 (8.9) 15 (6.1) 8 (4) 223 (7.5) 
Antimalarial combi 132 (13.1) 34 (4.3) 48 (11) 31 (9.8) 18 (7.3) 10 (5.1) 273 (9.1) 
Immunosuppressants mono 66 (6.6) 14 (1.8) 23 (5.3) 17 (5.4) 9 (3.6) 10 (5.1) 139 (4.6) 
Immunosuppressants combi 75 (7.5) 14 (1.8) 17 (3.9) 13 (4.1) 6 (2.4) 2 (1) 127 (4.2) 
 Mycophenolate mofetil 
 mono 
42 (4.2) 8 (1) 11 (2.5) 6 (1.9) 3 (1.2) 2 (1) 72 (2.4) 
 Mycophenolate mofetil 
 combi 
44 (4.4) 9 (1.1) 13 (3) 6 (1.9) 3 (1.2) 2 (1) 77 (2.6) 
 Azathioprine mono 17 (1.7) 6 (0.8) 9 (2.1) 8 (2.5) 5 (2) 7 (3.5) 52 (1.7) 
 Azathioprine combi 24 (2.4) 5 (0.6) 3 (0.7) 4 (1.3) 3 (1.2) 0 39 (1.3) 
 Cyclophosph. mono 2 (0.2) 0 3 (0.7) 2 (0.6) 1 (0.4) 1 (0.5) 9 (0.3) 
 Cyclophosph. combi 6 (0.6) 0 1 (0.2) 1 (0.3) 0 0 8 (0.3) 
 Tacrolimus mono 5 (0.5) 0 0 0 0 0 5 (0.2) 
 Tacrolimus combi 9 (0.9) 0 0 0 1 (0.4) 0 10 (0.3) 
 Cyclosporin mono 0 0 0 1 (0.3) 0 0 1 (0) 
 Cyclosporin combi 1 (0.1) 0 1 (0.2) 4 (1.3) 0 0 6 (0.2) 
bDMARDs monotherapy 174 (17.3) 228 (28.8) 53 (12.2) 63 (20) 44 ( 17.8) 43 ( 21.7) 605 ( 20.2) 
bDMARDs combination therapy 178 (17.7) 144 (18.2) 67 (15.4) 48 (15.2) 34 (13.8) 29 (14.7) 500 (16.7) 
TNF inhibitors mono 100 (10) 145 (18.3) 29 (6.7) 45 (14.3) 27 (10.9) 26 (13.1) 372 (12.4) 
TNF inhibitors combi 106 (10.5) 84 (10.6) 39 (9) 28 (8.9) 19 (7.7) 13 (6.6) 289 (9.7) 
Abatacept mono 14 (1.4) 6 (0.8) 1 (0.2) 5 (1.6) 0 0 26 (0.9) 
Abatacept combi 20 (2) 13 (1.6) 3 (0.7) 2 (0.6) 3 (1.2) 3 (1.5) 44 (1.5) 
B-cell affecting bDMARDs mono 29 (2.9) 26 (3.3) 10 (2.3) 1 (0.3) 8 (3.2) 3 (1.5) 77 (2.6) 
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B-cell affecting bDMARDs combi 37 (3.7) 22 (2.8) 20 (4.6) 9 (2.9) 8 (3.2) 10 (5.1) 106 (3.5) 
 Rituximab mono 26 (2.6) 26 (3.3) 10 (2.3) 1 (0.3) 7 (2.8) 3 (1.5) 73 (2.4) 
 Rituximab combi 24 (2.4) 20 (2.5) 19 (4.4) 7 (2.2) 8 (3.2) 8 (4) 86 (2.9) 
 Belimumab mono 3 (0.3) 0 0 0 1 (0.4) 0 4 (0.1) 
 Belimumab combi 13 (1.3) 2 (0.3) 1 (0.2) 2 (0.6) 1 (0.4) 2 (1) 21 (0.7) 
IL-6 inhibitors mono 11 (1.1) 18 (2.3) 3 (0.7) 4 (1.3) 3 (1.2) 6 (3) 45 (1.5) 
IL-6 inhibitors combi 12 (1.2) 11 (1.4) 2 (0.5) 3 (1) 3 (1.2) 0 31 (1) 
IL-1 inhibitors mono 0 9 (1.1) 1 (0.2) 0 1 (0.4) 0 11 (0.4) 
IL-1 inhibitors combi 2 (0.2) 0 1 (0.2) 2 (0.6) 0 0 5 (0.2) 
Other IL inhibitors 
( IL-17, Il-23, Il-12/23 inh.) mono 
19 (1.9) 24 (3) 9 (2.1) 7 (2.2) 5 (2) 8 (4) 72 (2.4) 
Other IL inhibitors 
( IL-17, Il-23, Il-12/23 inh.) combi 
3 (0.3) 14 (1.8) 2 (0.5) 6 (1.9) 1 (0.4) 3 (1.5) 29 (1) 
tsDMARDs mono 32 (3.2) 10 (1.3) 7 (1.6) 4 (1.3) 3 (1.2) 4 (2) 60 (2) 
tsDMARDs (*) combi 43 (4.3) 15 (1.9) 4 (0.9) 9 (2.9) 3 (1.2) 3 (1.5) 77 (2.6) 
 JAK inhibitors mono 26 (2.6) 10 (1.3) 7 (1.6) 4 (1.3) 2 (0.8) 4 (2) 53 (1.8) 
 JAK inhibitors combi 40 (4) 15 (1.9) 3 (0.7) 8 (2.5) 3 (1.2) 3 (1.5) 72 (2.4) 
 Apremilast mono 6 (0.6) 0 0 0 1 (0.4) 0 7 (0.2) 
 Apremilast combi 2 (0.2) 0 1 (0.2) 1 (0.3) 0 0 4 (0.1) 
No DMARD therapies 192 (19.1) 161 (20.3) 98 (22.5) 52 (16.5) 64 (25.9) 35 (17.7) 602 (20.1) 
        





























































Data are N (column %) for categorical variables or mean (SD) for continuous variables. Table includes all patients with a non-missing outcome and non-
missing values for age, sex and disease modifying anti-rheumatic drugs (DMARDs) (101 patients excluded). Data refers to patients with non-missing 
values for the respective variable, total N for patients with non-missing values is given in parentheses for variables with missing values. (*) Includes one 
patient on a study medication (Lenabasum). (#) Includes patients with a missing glucocorticoid dose.  
 
bDMARD, biologic disease modifying antirheumatic drugs; BMI, body mass index; csDMARD, conventional synthetic disease modifying antirheumatic 
drugs; combi, combination therapy; CTD, connective tissue diseases; DA, disease activity; DMARD, disease modifying antirheumatic drugs; GC, 
glucocorticoids; IL, interleukin; JAK, Janus kinase; JIA, juvenile idiopathic arthritis; mono, monotherapy; N, number; NSAID, non-steroidal anti-
inflammatory drugs; SLE, systemic lupus erythematosus; TNF; tumour necrosis factor; tsDMARD, targeted synthetic disease modifying antirheumatic 
drugs. 
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Supplementary table 3. Patient demographic and clinical characteristics stratified by main medication of interest 













N 1237 203 665 222 338 804 83 193 90 116 134 739 3729 
              
General              
Age [years] 58.3 (14.5) 59.5 (12.3) 53.3 (15.2) 59.0 (14.8) 50.1 (15.8) 51.1 (13.7) 59.0 (15.0) 56.2 (15.1) 57.7 (16.4) 50.1 (11.3) 58.3 (13.3) 62.8 (16.6) 57.0 (15.7) 




























              
Inflammatory joint 
diseases 





     
Rheumatoid arthritis 756 (61.1) 160 (78.8) 243 (36.5) 126 (56.8) 26 (7.7) 293 (36.4) 70 (84.3) 87 (45.1) 63 (70) 2 (1.7) 119 (88.8) 110 (14.9) 1394 (37.4) 
Spondyloartrhitis 74 (6) 4 (2) 6 (0.9) 35 (15.8) 6 (1.8) 271 (33.7) 2 (2.4) 0 2 (2.2) 43 (37.1) 4 (3) 59 (8) 431 (11.6) 
Psoriatic arthritis 177 (14.3) 23 (11.3) 8 (1.2) 38 (17.1) 1 (0.3) 182 (22.6) 4 (4.8) 1 (0.5) 0 70 (60.3) 9 (6.7) 38 (5.1) 440 (11.8) 




212 (95.5) 33 (9.8) 765 (95.1) 77 (92.8) 
 




239 (32.3) 2373 (63.6) 
Connective tissue 
diseases/ Vasculitis 





     
SLE 49 (4) 7 (3.4) 257 (38.6) 3 (1.4) 127 (37.6) 6 (0.7) 2 (2.4) 15 (7.8) 1 (1.1) 1 (0.9) 5 (3.7) 48 (6.5) 391 (10.5) 
CTDs (other than SLE) 104 (8.4) 4 (2) 171 (25.7) 5 (2.3) 134 (39.6) 19 (2.4) 6 (7.2) 52 (26.9) 1 (1.1) 0 3 (2.2) 156 (21.1) 533 (14.3) 
Vasculitis 44 (3.6) 7 (3.4) 7 (1.1) 5 (2.3) 53 (15.7) 14 (1.7) 0 39 (20.2) 21 (23.3) 0 0 161 (21.8) 326 (8.7) 
Total CTD 190 (15.4) 17 (8.4) 407 (61.2) 
 
13 (5.9) 294 (87) 39 (4.9) 8 (9.6) 104 (53.9) 23 (25.6) 1 (0.9) 7 (5.2) 353 (47.8) 1193 (32) 
Other RMDs              
Total 60 (4.9) 7 (3.4) 33 (5) 17 (7.7) 49 (14.5) 33 (4.1) 3 (3.6) 20 (10.4) 3 (3.3) 3 (2.6) 6 (4.5) 173 (23.4) 356 (9.5) 
              
Disease activity N=894 N=162 N=574 N=196 N=300 N=547 N=62 N=142 N=61 N=73 N=105 N=517 N=2758 
 Remission 307 (34.3) 40 (24.7) 146 (25.4) 50 (25.5) 66 (22) 184 (33.6) 14 (22.6) 36 (25.4) 16 (26.2) 20 (27.4) 19 (18.1) 215 (41.6) 893 (32.4) 
 Minimal/low 
DA 
413 (46.2) 84 (51.9) 310 (54) 100 (51) 138 (46) 265 (48.4) 32 (51.6) 64 (45.1) 25 (41) 33 (45.2) 56 (53.3) 211 (40.8) 1309 (47.5) 
 Moderate DA 157 (17.6) 31 (19.1) 91 (15.9) 38 (19.4) 71 (23.7) 89 (16.3) 10 (16.1) 26 (18.3) 16 (26.2) 19 (26) 26 (24.8) 56 (10.8) 448 (16.2) 
 Severe/high DA 17 (1.9) 7 (4.3) 27 (4.7) 8 (4.1) 25 (8.3) 9 (1.6) 6 (9.7) 16 (11.3) 4 (6.6) 1 (1.4) 4 (3.8) 35 (6.8) 108 (3.9) 
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Death 99 (8) 22 (10.8) 56 (8.4) 42 (18.9) 46 (13.6) 30 (3.7) 9 (10.8) 42 (21.8) 5 (5.6) 1 (0.9) 13 (9.7) 124 (16.8) 390 (10.5) 
              
Comorbidities N=1224 N=202 N=661 N=219 N=337 N=800 N=83 N=190 N=90 N=115 N=133 N=733 N=3700 
Hypertension 422 (34.5) 71 (35.1) 239 (36.2) 
 
85 (38.8) 127 (37.7) 196 (24.5) 
 
28 (33.7) 58 (30.5) 24 (26.7) 29 (25.2) 55 (41.4) 332 (45.3) 1307 (35.3) 
Cardiovascular disease 121 (9.9) 23 (11.4) 63 (9.5) 36 (16.4) 38 (11.3) 53 (6.6) 12 (14.5) 
 
25 (13.2) 13 (14.4) 9 (7.8) 12 (9) 146 (19.9) 442 (11.9) 
Cerebrovascular disease 31 (2.5) 7 (3.5) 19 (2.9) 9 (4.1) 11 (3.3) 13 (1.6) 1 (1.2) 5 (2.6) 3 (3.3) 2 (1.7) 4 (3) 31 (4.2) 109 (2.9) 
Chronic lung disease 216 (17.6) 48 (23.8) 136 (20.6) 
 
45 (20.5) 113 (33.5) 108 (13.5) 
 
17 (20.5) 64 (33.7) 7 (7.8) 13 (11.3) 34 (25.6) 137 (18.7) 719 (19.4) 
Chronic kidney disease 42 (3.4) 12 (5.9) 58 (8.8) 11 (5) 54 (16) 24 (3) 6 (7.2) 22 (11.6) 3 (3.3) 3 (2.6) 6 (4.5) 83 (11.3) 258 (7) 
Obesity (BMI ≥ 30) 187 (15.3) 30 (14.9) 108 (16.3) 38 (17.4) 55 (16.3) 148 (18.5) 
 
15 (18.1) 22 (11.6) 18 (20) 27 (23.5) 36 (27.1) 102 (13.9) 597 (16.1) 
Morbid obesity (BMI ≥ 
40) 
33 (2.7) 6 (3) 34 (5.1) 6 (2.7) 26 (7.7) 24 (3) 4 (4.8) 13 (6.8) 2 (2.2) 2 (1.7) 12 (9) 20 (2.7) 
122 (3.3) 
Diabetes 170 (13.9) 39 (19.3) 80 (12.1) 38 (17.4) 46 (13.6) 75 (9.4) 14 (16.9) 26 (13.7) 13 (14.4) 12 (10.4) 19 (14.3) 121 (16.5) 505 (13.6) 
Cancer 64 (5.2) 7 (3.5) 32 (4.8) 12 (5.5) 13 (3.9) 17 (2.1) 5 (6) 18 (9.5) 3 (3.3) 5 (4.3) 2 (1.5) 76 (10.4) 214 (5.8) 
Other comorbidities 267 (21.8) 43 (21.3) 138 (20.9) 63 (28.8) 98 (29.1) 209 (26.1) 
 
19 (22.9) 50 (26.3) 22 (24.4) 44 (38.3) 33 (24.8) 178 (24.3) 897 (24.2) 
              
DMARD therapies              
Methotrexate/Leflunomi
de 
1237 (100) 203 (100) 199 (29.9) 96 (43.2) 10 (3) 306 (38.1) 
 
41 (49.4) 61 (31.6) 32 (35.6) 30 (25.9) 61 (45.5) 0 1404 (37.7) 
Sulfasalazine 75 (6.1) 24 (11.8) 39 (5.9) 222 (100) 5 (1.5) 48 (6) 1 (1.2) 6 (3.1) 5 (5.6) 3 (2.6) 11 (8.2) 0 222 (6) 
Antimalarials 177 (14.3) 33 (16.3) 665 (100) 39 (17.6) 108 (32) 41 (5.1) 10 (12) 29 (15) 7 (7.8) 2 (1.7) 14 (10.4) 0 665 (17.8) 
Immunosuppressants 9 (0.7) 1 (0.5) 108 (16.2) 
 
5 (2.3) 338 (100) 17 (2.1) 2 (2.4) 27 (14) 0 1 (0.9) 2 (1.5) 0 338 (9.1) 
bDMARDs 424 (34.3) 63 (31) 109 (16.4) 64 (28.8) 59 (17.5) 804 (100) 83 (100) 193 (100) 90 (100) 116 (100) 1 (0.7) 0 1331 (35.7) 
tsDMARDs 52 (4.2) 12 (5.9) 14 (2.1) 12 (5.4) 3 (0.9) 0 0 1 (0.5) 0 1 (0.9) 134 (100) 0 147 (3.9) 
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Data are N (column %) for categorical variables or mean (SD) for continuous variables. Table includes all patients with a non-missing outcome and non-missing values for age, sex and disease modifying anti-rheumatic drugs 
(DMARDs) (101 patients excluded). Data refers to patients with non-missing values for the respective variable, total N for patients with non-missing values is given in parentheses for variables with missing values. (*) 
Includes one patient on a study medication (Lenabasum). (#) Includes patients with a missing glucocorticoid dose. 
 
ABA, Abatacept; bDMARD, biologic disease modifying antirheumatic drugs; BMI, body mass index; csDMARD, conventional synthetic disease modifying antirheumatic drugs; combi, combination therapy; CTD, connective tissue 
diseases; DA, disease activity; DMARD, disease modifying antirheumatic drugs; GC, glucocorticoids; IL-6i, interleukin-6 inhibitors; IL-17/23/12+23i, interleukin-17/23/12+23 inhibitors; IMMMUNOSUPPR, immunosuppressants; 
.JAKi, Janus kinase inhibitors; JIA, juvenile idiopathic arthritis; LEF, leflunomide;  MTX, methotrexate; mono, monotherapy; N, number; NSAID, non-steroidal anti-inflammatory drugs; RTX, rituximab; SLE, systemic lupus 
erythematosus; SSZ, sulfasalazine; TNFi; tumour necrosis factor inhibitors. 
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Supplementary table 4. Multivariable logistic regression analysis of factors associated with COVID-19-related death in patients with rheumatic diseases (excluding patients reported from France) 
 All Patients with inflammatory joint 
diseases (IJDs) 
Only patients with rheumatoid arthritis Patients with connective tissue diseases 
(CTDs) or vasculitis 
N deaths/patients (%) 324 / 2921 (11.1%) 186 / 1818 (10.2%) 146 / 1124 (13.0 %) 113 / 932 (12.1%) 
 N 
deaths/patients 
OR 95% CI 
N 
deaths/patients 
OR 95% CI 
N 
deaths/patients 
OR 95% CI 
N 
deaths/patients 
OR 95% CI 
Age, years 
Age ≤ 65 108 / 2018 1 [Reference] 52 / 1259 1 [Reference] 38 / 692 1 [Reference] 49 / 657 1 [Reference] 
65 years < Age ≤ 75  97 / 516 3.18 2.26 4.47 67 / 351 3.58 2.41 5.33 53 / 259 3.33 1.80 6.18 24 / 139 2.43 1.43 4.13 
Age > 75 119 / 387 5.77 4.03 8.28 67 / 208 7.22 4.89 10.66 55 / 173 6.31 3.77 10.54 40 / 136 4.34 2.11 8.91 
Male sex (vs. female) 131 / 919 1.39 1.00 1.95 74 / 603 1.39 1.01 1.91 50 / 279 1.27 0.85 1.89 44 / 232 1.38 0.91 2.08 
Ever smoked (vs. never)  135 / 873 1.12 0.85 1.49 85 / 576 1.15 0.79 1.67 71 / 373 1.27 0.87 1.86 39 / 234 1.13 0.70 1.82 
Comorbidities 
Hypertension alone or 
CVD alone 
125 / 954 1.08 0.85 1.38 67 / 568 1.03 0.69 1.54 54 / 375 1.05 0.70 1.59 53 / 337 1.40 0.95 2.08 
Hypertension and CVD 72 / 253 1.77 1.20 2.62 48 / 146 2.45 1.22 4.92 34 / 102 2.09 0.99 4.42 18 / 82 1.15 0.61 2.18 
Chronic lung disease 122 / 610 1.74 1.26 2.40 73 / 342 1.67 1.15 2.41 61 / 258 1.62 1.13 2.32 44 / 241 2.17 1.41 3.35 
Chronic kidney 
disease 
58 / 214 1.40 0.81 2.43 21 / 97 0.83 0.45 1.56 16 / 75 0.76 0.36 1.59 30 / 97 2.34 1.16 4.73 
Diabetes mellitus 79 / 433 1.26 0.76 2.08 47 / 267 1.23 0.86 1.77 32 / 182 1.00 0.63 1.58 21 / 126 1.01 0.52 1.96 
Rheumatic disease 





34 / 341 1.28 0.71 2.29  
n.a. 
 30 / 328 
1 [Reference] 
Vasculitis 49 / 254 0.75 0.54 1.05   43 / 233 0.65 0.40 1.08 
Other connective 
tissue diseases 
42 / 384 0.73 0.54 0.98   40 / 371 0.77 0.36 1.64 
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Psoriasis arthritis 16 / 355 0.72 0.49 1.05 16 / 363 0.75 0.50 1.13   
n.a. 




9 / 92 0.75 0.45 1.26 10 / 97 0.71 0.41 1.23   
Other rheumatic 
diseases (not IJDs / 
CTDs / vasculitis) 




disease activity (DA) vs. 
remission/low DA 
96 / 585 1.91 1.24 2.95 50 / 365 1.65 1.11 2.45 40 / 233 1.67 1.00 2.81 43 / 189 2.59 1.46 4.58 
Medication 
Methotrexate 38 / 444 1 [Reference] 33 / 366 1 [Reference] 27 / 273 1 [Reference] 5 / 69 1 [Reference] 
No DMARD therapy  94 / 578 1.91 1.29 2.84 30 / 188 1.99 1.18 3.36 19 / 90 2.01 1.16 3.49 49 / 266 2.76 1.32 5.78 
Leflunomide 12 / 82 1.53 0.83 2.81 10 / 75 1.40 0.65 3.01 9 / 62 1.46 0.68 3.15  n.a. 
Antimalarials  26 / 380 0.92 0.58 1.46 17 / 158 1.15 0.61 2.14 17 / 133 1.28 0.68 2.41 10 / 234 1.16 0.33 4.03 
Sulfasalazine 33 / 138 3.19 1.39 7.32 31 / 132 3.10 1.25 7.70 21 / 84 2.41 1.07 5.39  n.a. 
Immunosuppressants 36 / 252 1.98 1.20 3.24  n.a.  n.a. 30 / 227 1.87 0.75 4.65 
TNF inhibitors 26 / 574 0.76 0.45 1.28 23 / 544 0.73 0.36 1.46 15 / 235 0.85 0.37 1.96 3 / 34 1.22 0.19 7.68 
Abatacept 8 / 62 1.22 0.55 2.68 8 / 57 1.43 0.60 3.45 8 / 51 1.57 0.64 3.85  n.a. 
Rituximab 32 / 146 3.56 1.94 6.53 19 / 73 4.75 2.21 10.20 18 / 69 4.35 1.91 9.91 15 / 78 2.60 0.80 8.44 
Belimumab 1 / 25 0.62 0.15 2.53  n.a.  n.a. 1 / 25 0.80 0.15 4.33 
IL-6 inhibitors 4 / 61 0.94 0.36 2.43 1 / 49 0.33 0.03 3.39 1 / 44 0.33 0.03 3.25  
n.a. IL-17/IL-23/IL-12+23 
inhibitors  
1 / 77 0.29 0.03 2.41 1 / 75 0.31 0.04 2.43  
n.a. 
 
tsDMARDs 13 / 120 1.50 0.81 2.77 13 / 117 1.77 0.97 3.23 11 / 97 1.54 0.71 3.32  n.a. 
Glucocorticoids (GCs) 
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No GCs 148 / 1885 1 [Reference] 103 / 1301 1 [Reference] 76 / 700 1 [Reference] 31 / 465 1 [Reference] 
GCs 1-10mg/d 137 / 856 1.33 0.85 2.07 75 / 467 1.18 0.61 2.28 63 / 390 1.10 0.51 2.38 57 / 372 1.92 1.21 3.03 
GCs > 10 mg/d 40 / 180 1.73 1.10 2.71 9 / 50 1.07 0.48 2.36 7 / 34 0.97 0.42 2.22 28 / 111 2.40 1.32 4.38 
Missing values imputed via multiple imputation, patient numbers may thus be rounded. Effects significant at level α=0.05 are marked in bold. Patients were excluded from a particular analysis if the 
medication they received provided ≤ 20 patients for that analysis or if there were no deaths reported for that specific medication. 
CI, confidence interval; CTD, connective tissue diseases; CVD, cardiovascular disease; DA, disease activity; DMARD, disease modifying antirheumatic drugs; GC, glucocorticoids; IJD, inflammatory joint 
diseases;  IL, interleukin; JIA, juvenile idiopathic arthritis; N, number; OR, odds ratio; SLE, systemic lupus erythematosus; TNF; tumour necrosis factor; tsDMARD, targeted synthetic disease modifying 
antirheumatic drugs. 
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Supplementary table 5. Multivariable logistic regression analysis of factors associated with COVID-19-related death in patients with rheumatic diseases in patients with no missing values 
(complete case analysis) 
 All Patients with inflammatory joint 
diseases (IJDs) 
Only patients with rheumatoid arthritis Patients with connective tissue diseases 
(CTDs) or vasculitis 
N deaths/patients (%) 207 / 2081 (9.9%) 113 / 1232 (9.1%) 87 / 770 (11.3%) 74 / 699 (10.6%) 
 N deaths/ 
patients 
OR 95% CI 
N deaths/ 
patients 
OR 95% CI 
N deaths/ 
patients 
OR 95% CI 
N deaths/ 
patients 
OR 95% CI 
Age, years 
Age ≤ 65 69 / 1476 1 [Reference] 33 / 868 1 [Reference] 24 / 493 1 [Reference] 33 / 518 1 [Reference] 
65 years < Age ≤ 75  58 / 357 3.03 1.99 4.62 37 / 236 2.81 1.78 4.44 28 / 172 2.52 1.31 4.85 15 / 100 2.12 1.06 4.26 
Age > 75 80 / 248 6.71 4.91 9.17 43 / 128 7.17 3.65 14.09 35 / 105 5.93 2.47 14.22 26 / 81 5.60 2.89 10.86 
Male sex (vs. female) 81 / 614 1.30 0.96 1.76 45 / 385 1.57 1.05 2.35 29 / 175 1.35 0.79 2.32 26 / 163 1.07 0.65 1.75 
Ever smoked (vs. 
never)  
85 / 597 1.16 0.84 1.60 50 / 377 1.20 0.80 1.80 42 / 247 1.44 1.02 2.03 27 / 172 1.35 0.69 2.63 
Comorbidities 
Hypertension alone 
or CVD alone 
82 / 687 1.14 0.93 1.41 41 / 387 1.11 0.74 1.66 33 / 258 1.17 0.76 1.82 37 / 260 1.67 1.09 2.55 
Hypertension and 
CVD 
48 / 168 2.04 1.58 2.63 34 / 97 3.24 1.73 6.08 24 / 67 3.05 1.33 6.96 10 / 53 1.06 0.61 1.84 
Chronic lung disease 83 / 453 1.76 1.37 2.27 42 / 232 1.39 1.02 1.90 34 / 175 1.32 0.95 1.83 37 / 194 2.80 1.88 4.16 
Chronic kidney 
disease 
38 / 135 1.59 0.94 2.69 17 / 55 1.49 0.97 2.31 13 / 42 1.53 1.03 2.29 16 / 61 2.04 0.77 5.41 
Diabetes mellitus 48 / 302 1.13 0.73 1.73 32 / 185 1.24 0.91 1.69 21 / 125 0.88 0.59 1.30 10 / 89 0.69 0.28 1.70 
Rheumatic disease 





19 / 265 0.99 0.409 2.37  
n.a. 
 16 / 256 
1 [Reference] 
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Vasculitis 31 / 163 1.02 0.59 1.77   26 / 146 1.03 0.49 2.20 
Other connective 
tissue diseases 
33 / 307 0.88 0.55 1.43   32 / 297 1.14 0.55 2.39 
Psoriasis arthritis 11 / 230 0.80 0.53 1.20 11 / 236 0.69 0.45 1.06   
n.a. 




5 / 68 0.87 0.42 1.81 6 / 70 0.79 0.41 1.55   
Other rheumatic 
diseases (not IJDs / 
CTDs / vasculitis) 




disease activity (DA) vs. 
remission/low DA 
65 / 422 2.03 1.33 3.10 34 / 240 1.96 1.24 3.09 27 / 159 1.98 1.13 3.48 28 / 145 2.73 1.93 3.86 
Medication 
Methotrexate 24 / 302 1 [Reference] 22 / 252 1 [Reference] 17 / 182 1 [Reference] 2 / 46 1 [Reference] 
No DMARD therapy  58 / 385 1.56 1.09 2.23 17 / 122 1.54 0.90 2.62 11 / 54 1.64 0.81 3.32 30 / 184 4.23 1.55 11.53 
Leflunomide 7 / 51 1.35 0.76 2.41 5 / 47 0.87 0.48 1.60 4 / 41 0.76 0.41 1.40  n.a. 
Antimalarials  19 / 296 1.02 0.67 1.54 12 / 117 1.00 0.56 1.79 12 / 96 1.09 0.59 2.05 8 / 190 2.40 0.73 7.93 
Sulfasalazine 16 / 90 2.77 0.88 8.69 15 / 87 2.43 0.78 7.53 11 / 51 2.16 0.72 6.46  n.a. 
Immunosuppressants 26 / 193 1.99 1.08 3.68  n.a.  n.a. 21 / 173 3.25 1.18 9.00 
TNF inhibitors 19/ 447 0.75 0.43 1.31 17 / 425 0.65 0.33 1.29 10 / 188 0.68 0.24 1.94 2 / 24 2.26 0.12 42.16 
Abatacept 6 / 49 1.17 0.43 3.19 6 / 46 1.12 0.35 3.61 6 / 40 1.21 0.35 4.20  n.a. 
Rituximab 17 / 104 2.43 1.64 3.58 8 / 45 2.99 1.36 6.55 7 / 42 2.60 1.16 5.81 10 / 62 3.48 1.23 9.88 




1 / 21 2.11 0.32 13.96 
IL-6 inhibitors 3 / 50 0.78 0.338 1.81    n.a. 
tsDMARDs 11 / 101 1.58 0.86 2.90 11 / 98 1.76 1.01 3.05 9 / 83 1.41 0.74 2.70  
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No GCs 93 / 1394 1 [Reference] 59 / 917 1 [Reference] 41 / 511 1 [Reference] 22 / 373 1 [Reference] 
GCs 1-10mg/d 90 / 561 1.63 1.14 2.33 47 / 282 1.44 0.66 3.15 41 / 237 1.54 0.63 3.77 37 / 248 2.32 1.30 4.11 
GCs > 10 mg/d 24 / 126 1.58 0.91 2.74 7 / 33 1.54 0.48 4.98 5 / 22 1.35 0.48 3.80 15 / 78 2.06 1.04 4.09 
Effects significant at level α=0.05 are marked in bold. Patients were excluded from a particular analysis if the medication they received provided ≤ 20 patients for that analysis or if there were no deaths 
reported for that specific medication. 
CI, confidence interval; CTD, connective tissue diseases; CVD, cardiovascular disease; DA, disease activity; DMARD, disease modifying antirheumatic drugs; GC, glucocorticoids; IJD, inflammatory joint 
diseases;  IL, interleukin; JIA, juvenile idiopathic arthritis; N, number; OR, odds ratio; SLE, systemic lupus erythematosus; TNF; tumour necrosis factor; tsDMARD, targeted synthetic disease modifying 
antirheumatic drugs. 
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Supplementary table 6. Multivariable logistic regression analysis of factors associated with COVID-19-related death in patients with rheumatic diseases with a confirmed or highly likely COVID-
19 diagnosis 
 All Patients with inflammatory joint 
diseases (IJDs) 
Only patients with rheumatoid arthritis Patients with connective tissue 
diseases (CTDs) or vasculitis 
N deaths/patients (%) 345 / 2968 (11.6%) 184 / 1619 (10.2%) 143 / 946 (13.1%) 139 / 999 (13.9%) 
 N 
deaths/patients 
OR 95% CI 
N 
deaths/patients 
OR 95% CI 
N 
deaths/patients 
OR 95% CI 
N 
deaths/patients 
OR 95% CI 
Age, years 
Age ≤ 65 107 / 1971 1 [Reference] 48 / 1204 1 [Reference] 35 / 627 1 [Reference] 53 / 666 1 [Reference] 
65 years < Age ≤ 75  98 / 545 2.87 1.92 4.29 62 / 358 3.43 2.43 4.84 48 / 267 2.90 1.61 5.23 32 / 161 2.37 1.27 4.43 
Age > 75 140 / 452 5.40 3.58 8.14 74 / 241 7.16 4.81 10.66 60 / 195 5.91 3.76 9.29 54 / 172 3.82 1.80 8.12 
Male sex (vs. female) 146 / 962 1.47 1.12 1.94 71 / 607 1.27 0.90 1.81 47 / 282 1.16 0.76 1.75 60 / 261 1.70 0.99 2.93 
Ever smoked (vs. 
never)  
119 / 740 1.13 0.85 1.50 69 / 468 1.20 0.85 1.70 58 / 310 1.33 0.98 1.79 39 / 213 0.99 0.64 1.52 
Comorbidities 
Hypertension alone 
or CVD alone 
138 / 962 1.16 0.87 1.54 67 / 553 1.00 0.72 1.37 55 / 369 1.09 0.74 1.62 63 / 357 1.45 0.96 2.19 
Hypertension and 
CVD 
80 / 271 1.83 1.34 2.51 47 / 151 2.16 1.17 3.98 34 / 108 2.05 1.00 4.19 27 / 96 1.46 0.75 2.83 
Chronic lung disease 122 / 602 1.68 1.23 2.29 66 / 334 1.47 0.95 2.27 55 / 246 1.43 0.92 2.23 51 / 243 2.08 1.48 2.93 
Chronic kidney 
disease 
69 / 233 1.57 0.97 2.57 24 / 95 1.18 0.61 2.29 18 / 71 1.08 0.51 2.28 38 / 116 2.07 1.18 3.62 
Diabetes mellitus 90 / 461 1.36 0.89 2.08 50 / 274 1.29 0.92 1.81 35 / 188 1.07 0.70 1.63 31 / 147 1.28 0.61 2.69 
Rheumatic disease 





35 / 336 1.31 0.77 2.23  
n.a. 
 31 / 326 
1 [Reference] 
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Vasculitis 63 / 284 0.92 0.67 1.26   60 / 277 0.81 0.49 1.35 
Other connective 
tissue diseases 
50 / 407 0.83 0.62 1.12   48 / 396 0.80 0.40 1.61 
Psoriasis arthritis 17 / 324 0.76 0.60 0.97 17 / 331 0.85 0.61 1.17   
n.a. 




9 / 84 0.86 0.57 1.31 10 / 89 0.90 0.57 1.44   
Other rheumatic 
diseases (not IJDs / 
CTDs / vasculitis) 




disease activity (DA) vs. 
remission/low DA 
97 / 575 1.77 1.15 2.73 47 / 337 1.63 1.06 2.50 37 / 206 1.63 0.98 2.71 47 / 204 2.11 1.28 3.46 
Medication 
Methotrexate  45 / 476 1 [Reference] 39 / 387 1 [Reference] 32 / 279 1 [Reference] 6 / 80 1 [Reference] 
No DMARD therapy  109 / 620 1.88 1.31 2.68 28 / 187 1.58 1.01 2.46 17 / 88 1.55 0.92 2.61 64 / 309 3.22 1.58 6.56 
Leflunomide 10 / 75 1.38 0.79 2.40 8 / 68 1.15 0.60 2.20 7 / 56 1.12 0.56 2.26  n.a. 
Antimalarials  24 / 360 0.86 0.52 1.43 15 / 138 1.02 0.51 2.03 15 / 116 1.09 0.54 2.18 10 / 231 1.30 0.43 3.88 
Sulfasalazine 28 / 119 3.16 1.36 7.37 26 / 113 2.91 1.14 7.43 18 / 75 2.25 0.98 5.17  n.a. 
Immunosuppressants 36 / 238 1.99 1.27 3.13  n.a.  n.a. 31 / 213 2.46 1.11 5.42 
TNF inhibitors 29 / 575 0.92 0.57 1.49 25 / 544 0.83 0.45 1.54 15 / 229 0.87 0.37 2.05 4 / 34 2.09 0.33 13.30 
Abatacept 8 / 68 1.06 0.57 1.96 8 / 62 1.14 0.57 2.29 8 / 56 1.21 0.57 2.58  n.a. 
Rituximab 35 / 160 3.28 1.89 5.69 19 / 72 5.32 2.54 11.13 18 / 68 4.80 2.24 10.29 19 / 89 3.29 1.04 10.43 
Belimumab 1 / 23 0.66 0.19 2.31  n.a.  n.a. 1 / 23 1.09 0.22 5.39 
IL-6 inhibitors 5 / 66 0.91 0.43 1.90 1 / 47 0.29 0.03 2.80 1 / 42 0.29 0.03 2.79 4 / 21 2.72 0.91 8.09 
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tsDMARDs 14 / 114 1.66 0.85 3.21 14 / 111 1.80 0.96 3.34 12 / 91 1.54 0.66 3.60  n.a. 
Glucocorticoids (GCs) 
No GCs 148 / 1884 1 [Reference] 97 / 1298 1 [Reference] 67 / 681 1 [Reference] 36 / 467 1 [Reference] 
GCs 1-10mg/d 151 / 883 1.39 0.93 2.06 76 / 454 1.32 0.71 2.46 67 / 371 1.38 0.64 3.00 70 / 406 1.74 1.14 2.67 
GCs > 10 mg/d 46 / 200 1.68 1.11 2.56 11 / 51 1.41 0.68 2.90 9 / 38 1.38 0.59 3.22 33 / 126 2.16 1.21 3.88 
Missing values imputed via multiple imputation, patient numbers may thus be rounded. Effects significant at level α=0.05 are marked in bold. Patients were excluded from a particular analysis if the 
medication they received provided ≤ 20 patients for that analysis or if there were no deaths reported for that specific medication. 
CI, confidence interval; CTD, connective tissue diseases; CVD, cardiovascular disease; DA, disease activity; DMARD, disease modifying antirheumatic drugs; GC, glucocorticoids; IJD, inflammatory joint 
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Supplementary table 7. Multivariable logistic regression analysis of factors associated with COVID-19-related death or invasive ventilation in patients with rheumatic diseases  
 All Patients with inflammatory joint 
diseases (IJDs) 
Only patients with rheumatoid 
arthritis 
Patients with connective tissue 
diseases (CTDs) or vasculitis 
N deaths or invasive 
ventilations (IV) 
/patients (%) 
451 / 3075 (14.7%) 248 / 1970 (12.6%) 188 / 1148 (16.4%) 170 / 925 (18.4%) 
 N deaths or  
IVs / patients OR 95% CI 
N deaths or  
IVs / patients OR 95% CI 
N deaths or  
IVs/patients OR 95% CI 
N deaths or  
IVs / 
patients 
OR 95% CI 
Age, years 
Age ≤ 65 168 / 2173 1 [Reference] 81 / 1425 1 [Reference] 51 / 721 1 [Reference] 80 / 638 1 [Reference] 
65 years < Age ≤ 75  120 / 507 2.55 2.00 3.26 78 / 339 2.95 2.14 4.06 62 / 253 3.09 1.96 4.88 90 / 287 1.54 1.14 2.09 
Age > 75 163 / 395 5.19 3.35 8.03 89 / 206 7.22 3.90 13.35 75 / 174 7.11 3.65 13.85 58 / 146 3.21 2.08 4.96 
Male sex (vs. female) 184 / 977 1.50 1.12 2.00 92 / 652 1.29 0.91 1.83 61 / 287 1.20 0.74 1.96 72 / 242 1.76 1.18 2.60 
Ever smoked (vs. 
never)  
161 / 821 0.98 0.74 1.30 96 / 541 0.99 0.70 1.39 78 / 344 1.10 0.74 1.63 51 / 222 1.01 0.65 1.58 
Comorbidities 
Hypertension alone 
or CVD alone 
184 / 927 1.33 1.02 1.74 94 / 560 1.22 0.86 1.72 74 / 371 1.15 0.80 1.66 79 / 323 1.53 1.13 2.06 
Hypertension and 
CVD 
95 / 252 1.90 1.25 2.88 57 / 144 2.33 1.20 4.53 41 / 101 1.96 0.93 4.15 30 / 82 1.55 0.74 3.22 
Chronic lung disease 158 / 590 1.80 1.38 2.35 91 / 328 1.87 1.26 2.78 74 / 234 1.76 1.21 2.56 62 / 233 2.11 1.52 2.93 
Chronic kidney 
disease 
86 / 211 2.00 1.24 3.22 30 / 93 1.13 0.61 2.11 23 / 69 1.01 0.48 2.11 46 / 98 3.16 1.69 5.90 
Diabetes mellitus 108 / 393 1.44 0.97 2.14 62 / 246 1.30 1.02 1.67 44 / 171 1.17 0.80 1.71 35 / 114 1.42 0.61 3.31 
Rheumatic disease 
Rheumatoid arthritis 180 / 1107 1 [Reference] 188 / 1150 1 [Reference]  n.a.  n.a. 
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46 / 322 1.26 0.83 1.91  
n.a. 
 
42 / 310 1 [Reference] 
Vasculitis 72 / 267 0.77 0.59 1.02   65 / 246 0.74 0.50 1.09 
Other connective 
tissue diseases 
66 / 381 0.89 0.62 1.28   63 / 369 0.95 0.54 1.65 
Psoriasis arthritis 27 / 362 0.74 0.51 1.07 27 / 369 0.78 0.51 1.18   
n.a. 




13 / 88 1.04 0.72 1.49 15 / 93 1.13 0.83 1.54   
Other rheumatic 
diseases (not IJDs / 
CTDs / vasculitis) 




disease activity (DA) vs. 
remission/low DA 
119 / 592 1.57 1.13 2.19 60 / 380 1.35 0.96 1.89 48 / 235 1.32 0.88 1.98 53 / 182 1.98 1.21 3.24 
Medication 
Methotrexate  56 / 468 1 [Reference] 48 / 390 1 [Reference] 39 / 289 1 [Reference] 8 / 70 1 [Reference] 
No DMARD therapy  139 / 622 1.96 1.26 3.06 41 / 208 1.93 1.15 3.23 25 / 92 2.00 1.18 3.40 75 / 287 2.77 1.48 5.19 
Leflunomide 15 / 71 1.83 0.96 3.48 13 / 66 1.72 0.81 3.69 12 / 56 1.86 0.92 3.78  n.a. 
Antimalarials  35 / 357 1.02 0.67 1.56 20 / 142 1.13 0.61 2.10 19 / 117 1.25 0.67 2.31 17 / 225 1.53 0.67 3.48 
Sulfasalazine 37 / 120 3.67 1.85 7.26 35 / 113 3.67 1.75 7.70 24 / 70 3.04 1.43 6.45  n.a. 
Immunosuppressants 45 / 231 1.80 1.19 2.72  n.a.  n.a. 38 / 209 1.70 0.91 3.18 
TNF inhibitors 39 / 692 0.86 0.53 1.37 34 / 657 0.83 0.48 1.43 22 / 254 0.98 0.52 1.86 6 / 37 1.73 0.33 9.04 
Abatacept 11 / 65 1.28 0.61 2.71 11 / 62 1.40 0.63 3.12 11 / 58 1.55 0.71 3.42  n.a. 
Rituximab 46 / 144 4.31 2.48 7.49 25 / 72 5.99 3.00 11.96 24 / 69 6.04 3.01 12.09 23 / 75 3.15 1.12 8.90 
Belimumab 3 / 22 1.84 0.58 5.87  n.a.  n.a. 3 / 22 2.25 0.73 6.98 
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IL-6 inhibitors 5 / 77 0.75 0.34 1.63 1 / 60 0.22 0.02 2.09 1 / 55 0.22 0.02 2.14  
n.a. IL-17/IL-23/IL-12+23 
inhibitors  
6 / 92 1.42 0.59 3.43 6 / 89 1.58 0.63 3.96  
n.a. 
 
tsDMARDs 17 / 125 1.45 0.81 2.59 17 / 122 1.67 0.94 2.97 14 / 99 1.51 0.76 3.02  n.a. 
Glucocorticoids (GCs) 
No GCs 202 / 2032 1 [Reference] 136 / 1450 1 [Reference] 90 / 722 1 [Reference] 45 / 452 1 [Reference] 
GCs 1-10mg/d 191 / 860 1.45 1.03 2.04 99 / 468 1.31 0.72 2.38 87 / 389 1.37 0.68 2.73 86 / 362 2.02 1.44 2.84 
GCs > 10 mg/d 58 / 183 2.11 1.44 3.11 13 / 53 1.47 0.58 3.74 11 / 37 1.74 0.56 5.40 39 / 111 2.51 1.47 4.27 
Living patients with missing values for invasive ventilation excluded from the model (dependent variable unknown). Missing values in other variables imputed via multiple imputation, patient 
numbers may thus be rounded. Effects significant at level α=0.05 are marked in bold. Patients were excluded from a particular analysis if the medication they received provided ≤ 20 patients for 
that analysis or if there were no deaths reported for that specific medication. 
CI, confidence interval; CTD, connective tissue diseases; CVD, cardiovascular disease; DA, disease activity; DMARD, disease modifying antirheumatic drugs; GC, glucocorticoids; IJD, inflammatory 
joint diseases;  IL, interleukin; JIA, juvenile idiopathic arthritis; N, number; OR, odds ratio; SLE, systemic lupus erythematosus; TNF; tumour necrosis factor; tsDMARD, targeted synthetic disease 
modifying antirheumatic drugs. 
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Supplementary table 8. Multivariable logistic regression analysis of factors associated with COVID-19-related death in all patients with a reduced number of regressor variables 
 All Patients with inflammatory joint 
diseases (IJDs) 
Only patients with rheumatoid arthritis Patients with connective tissue 
diseases (CTDs) or vasculitis 
N deaths/patients (%) 384/3705 (10.4%) 211/2348 (9.0%) 166/1371 (12.1%) 147/1157 (12.7%) 
 N 
deaths/patients 
OR 95% CI 
N 
deaths/patients 
OR 95% CI 
N 
deaths/patients 
OR 95% CI 
N 
deaths/patients 
OR 95% CI 
Age, years 
Age ≤ 65 118 / 2565 1 [Reference] 55 / 1657 1 [Reference] 40 / 840 1 [Reference] 56 / 779 1 [Reference] 
Age > 65 266 / 1140 4.10 3.06 5.49 156 / 691 5.00 3.63 6.88 126 / 531 4.40 2.74 7.08 91 / 378 3.15 1.91 5.18 
Male sex (vs. female) 161 / 1188 1.41 1.08 1.86 82 / 788 1.27 0.94 1.72 55 / 345 1.14 0.77 1.70 63 / 296 1.64 0.97 2.77 
Ever smoked (vs. never)  140 / 922 1.18 0.89 1.56 84 / 607 1.21 0.88 1.66 71 / 385 1.38 1.00 1.92 42 / 248 1.07 0.63 1.81 
Comorbidities 
Hypertension alone or 
CVD alone 
155 / 1150 1.23 0.91 1.66 79 / 690 1.08 0.77 1.51 66 / 454 1.16 0.78 1.74 69 / 406 1.58 1.06 2.35 
Hypertension and CVD 89 / 301 2.13 1.42 3.18 53 / 168 2.66 1.54 4.60 38 / 118 2.48 1.34 4.56 28 / 106 1.65 0.80 3.43 
Chronic lung disease 136 / 721 1.63 1.21 2.20 76 / 406 1.51 1.01 2.26 63 / 293 1.45 0.96 2.20 54 / 285 1.92 1.37 2.69 
Chronic kidney disease 76 / 259 1.84 1.07 3.19 27 / 111 1.25 0.59 2.64 21 / 83 1.17 0.50 2.75 41 / 124 2.46 1.41 4.30 
Diabetes mellitus 96 / 508 1.35 0.87 2.10 55 / 313 1.27 0.93 1.73 39 / 213 1.06 0.71 1.57 32 / 154 1.37 0.65 2.89 
Rheumatic disease 





36 / 391 1.10 0.67 1.81  
n.a. 
 32 / 378 
1 [Reference] 
Vasculitis 67 / 325 0.85 0.64 1.11   
115 / 479 0.89 0.53 1.49 Other connective 
tissue diseases 
53 / 473 0.75 0.57 0.97   
Psoriasis arthritis 19 / 429 0.66 0.49 0.90 19 / 437 0.73 0.52 1.04   n.a. 
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10 / 109 0.73 0.44 1.22 11 / 114 0.70 0.40 1.23   
Other rheumatic 
diseases (not IJDs / 
CTDs / vasculitis) 




disease activity (DA) vs. 
remission/low DA 
109 / 722 1.84 1.31 2.59 54 / 453 1.49 1.09 2.02 44 / 274 1.49 0.99 2.23 51 / 230 2.54 1.63 3.95 
Medication 
Methotrexate  47 / 595 1 [Reference] 41 / 487 1 [Reference] 34 / 354 1 [Reference] 6 / 94 1 [Reference] 
No DMARD therapy  124 / 739  2.20 1.55 3.12 38 / 239 2.14 1.44 3.17 25 / 110 2.12 1.36 3.29 67 / 353 3.43 1.72 6.85 
Leflunomide 12 / 90 1.47 0.81 2.66 10 / 83 1.27 0.62 2.61 9 / 68 1.32 0.63 2.73  n.a. 
Antimalarials  27 /426 0.96 0.64 1.43 17 / 167 1.07 0.59 1.93 17 / 141 1.15 0.63 2.10 11 / 271 1.46 0.50 4.23 
Sulfasalazine 33 / 144 3.49 1.64 7.45 31 / 137 3.22 1.44 7.23 21 / 85 2.43 1.17 5.04  n.a. 
Immunosuppressants 38 / 276 2.18 1.44 3.32  n.a.  n.a. 32 / 247 2.54 1.15 5.63 
Rituximab 42 / 192 3.77 2.23 6.36 22 / 90 4.91 2.60 9.25 21 / 86 4.57 2.35 8.92 22 / 104 3.68 1.24 10.92 
TNF inhibitors 30 / 803 0.82 0.52 1.29 26 / 764 0.73 0.41 1.29 16 / 292 0.77 0.37 1.60 
9 / 89 2.04 0.60 6.92 Belimumab  
16 / 313 0.82 0.47 1.42 
 n.a.  n.a. 
IL-6 inhibitors  
11 / 255 0.69 0.35 1.36 







tsDMARDs 15 / 145 1.38 0.80 2.36 15 / 142 1.45 0.85 2.47 13 / 118 1.28 0.66 2.49 
Glucocorticoids (GCs) 
No GCs 165 / 2417 1 [Reference] 109 / 1721 1 [Reference] 78 / 863 1 [Reference] 38 / 551 1 [Reference] 
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Glucorticoids 219 / 1288 1.50 1.07 2.10 102 / 627 1.46 0.86 2.47 88 / 508 1.44 0.74 2.80 109 / 606 1.77 1.28 2.46 
Missing values imputed via multiple imputation, patient numbers may thus be rounded. Effects significant at level α=0.05 are marked in bold. Patients were excluded from a particular analysis if 
the medication they received provided ≤ 20 patients for that analysis or if there were no deaths reported for that specific medication. 
CI, confidence interval; CTD, connective tissue diseases; CVD, cardiovascular disease; DA, disease activity; DMARD, disease modifying antirheumatic drugs; GC, glucocorticoids; IJD, inflammatory 
joint diseases;  IL, interleukin; JIA, juvenile idiopathic arthritis; N, number; OR, odds ratio; SLE, systemic lupus erythematosus; TNF; tumour necrosis factor; tsDMARD, targeted synthetic disease 
modifying antirheumatic drugs. 
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Supplementary table 9. Multivariable logistic regression analysis of factors associated with COVID-19 death in patients from the six countries providing the largest number of patients, considering 
country effects, with an otherwise reduced number of regressor variables 
 All Patients with inflammatory joint 
diseases (IJDs) 
Only patients with rheumatoid arthritis Patients with connective tissue diseases 
(CTDs) or vasculitis 
N deaths/patients (%) 306 / 2974 (10.3%) 170 / 1903 (8.9%) 134 / 1102 (12.2%) 117 / 927 (12.6%) 
 N 
deaths/patients 
OR 95% CI 
N 
deaths/patients 
OR 95% CI 
N 
deaths/patients 
OR 95% CI 
N 
deaths/patients 
OR 95% CI 
Age, years 
Age ≤ 65 76 / 2015 1 [Reference] 36 / 1321 1 [Reference] 25 / 658 1 [Reference] 36 / 597 1 [Reference] 
Age > 65 230 / 959 4.57 3.24 6.45 134 / 582 5.83 3.63 9.37 109 / 444 5.15 3.03 8.75 28 / 160 2.76 1.59 4.80 
Male sex (vs. female) 141 / 951 1.68 1.26 2.24 71 / 640 1.41 0.95 2.08 47 / 283 1.24 0.77 1.98 56 / 239 2.03 1.28 3.21 
Ever smoked (vs. never)  118 / 745 1.15 0.82 1.60 73 / 500 1.10 0.71 1.70 61 / 323 1.22 0.73 2.03 36 / 207 1.09 0.59 2.03 
Comorbidities 
Hypertension alone or 
CVD alone 
130 / 941 1.41 1.01 1.96 68 / 572 1.25 0.79 1.98 56 / 369 1.41 0.85 2.35 56 / 326 1.94 1.13 3.33 
Hypertension and CVD 73 / 259 2.16 1.41 3.31 43 / 141 2.58 1.43 4.68 32 / 100 2.60 1.34 5.04 26 / 100 2.09 1.07 4.11 
Lung disease 115 / 614 1.58 1.16 2.16 63 / 344 1.46 0.94 2.25 53 / 245 1.43 0.89 2.30 47 / 250 1.83 1.12 2.99 
Chronic kidney disease 59 / 212 1.73 1.12 2.67 24 / 97 1.32 0.68 2.57 19 / 72 1.28 0.63 2.62 30 / 96 2.08 1.09 3.96 
Diabetes mellitus 78 / 410 1.26 0.89 1.79 46 / 258 1.31 0.84 2.06 35 / 181 1.23 0.74 2.04 25 / 122 1.09 0.57 2.07 
Rheumatic disease 





18 / 299 0.78 0.39 1.55  
n.a. 
 15 / 288 
1 [Reference] 
Vasculitis 60 / 272 0.81 0.50 1.30   
102 / 639 1.33 0.65 2.73 Other connective 
tissue diseases 
47 / 384 0.93 0.58 1.47   
Psoriasis arthritis 17 / 353 0.70 0.38 1.30 17 / 360 0.81 0.43 1.54   n.a. 
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8 / 95 0.68 0.30 1.58 9 / 100 0.66 0.28 1.57   
Other rheumatic 
diseases (not IJDs / 
CTDs / vasculitis) 




disease activity (DA) vs. 
remission/low DA 
87 / 569 1.84 1.26 2.69 48 / 370 1.64 1.04 2.60 39 / 220 1.62 0.98 2.69 36 / 170 2.21 1.18 4.13 
Medication 
Methotrexate 34 / 477 1 [Reference] 28 / 387 1 [Reference] 23 / 278 1 [Reference] 6 / 77 1 [Reference] 
No DMARD therapy  101 / 602 2.61 1.61 4.26 32 / 198 2.75 1.46 5.16 21 / 94 2.40 1.14 5.06 56 / 302 2.82 1.22 6.49 
Leflunomide 10 / 64 2.32 0.98 5.50 8 / 59 1.78 0.71 4.45 8 / 48 2.16 0.81 5.76  n.a. 
Antimalarials  18 / 312 1.15 0.59 2.22 14 / 125 1.32 0.61 2.85 14 / 105 1.33 0.59 3.02 4 / 197 0.90 0.24 3.37 
Sulfasalazine 27 / 93 5.07 2.64 9.74 26 / 88 5.10 2.55 10.20 18 / 51 3.96 1.72 9.12  n.a. 
Immunosuppressants 28 / 212 2.94 1.53 5.63  n.a.  n.a. 23 / 192 2.59 1.02 6.58 
Rituximab 35 / 159 4.38 2.37 8.10 16 / 74 4.65 2.02 10.71 15 / 70 4.45 1.84 10.77 21 / 89 4.17 1.56 11.09 
TNF inhibitors 24 / 660 1.10 0.61 2.00 21 / 631 0.99 0.52 1.91 13 / 244 1.04 0.49 2.20 
7 / 71 2.13 0.65 6.93 Belimumab  
14 / 268 1.25 0.62 2.51 
 n.a.  n.a. 
IL-6 inhibitors  
10 / 216 1.05 0.46 2.40 







tsDMARDs 15 / 136 2.32 1.08 4.99 15 / 133 2.32 1.05 5.12 13 / 110 1.97 0.87 4.51 
Glucocorticoids (GCs)  1
No GCs 120 / 1959 1 [Reference] 80 / 1406 1 [Reference] 55 / 701 1 [Reference] 30 / 454 1 [Reference]  
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Glucorticoids 186 / 1015 1.92 1.40 2.63 90 / 497 1.99 1.33 2.98 79 / 401 2.16 1.38 3.36 87 / 473 1.74 1.02 2.94 
Countries 
USA 68 / 1001 1 [Reference] 36 / 568 1 [Reference] 31 / 380 1 [Reference] 27 / 380 1 [Reference] 
France 60 / 784 1.24 0.82 1.89 25 / 530 0.95 0.52 1.72 20 / 247 0.95 0.49 1.83 31 / 209 1.80 0.91 3.56 
UK 90 / 433 2.71 1.79 4.10 57 / 303 2.38 1.39 4.07 45 / 185 2.34 1.27 4.31 24 / 103 3.08 1.48 6.40 
Italy 52 / 312 1.87 1.15 3.02 29 / 196 1.65 0.84 3.24 21 / 103 1.67 0.75 3.71 22 / 110 2.11 0.97 4.61 
Spain 21 / 246 1.02 0.55 1.86 10 / 156 0.68 0.29 1.62 7 / 88 0.50 0.19 1.31 10 / 84 1.53 0.62 3.76 
Germany 15 / 198 1.02 0.54 1.94 13 / 150 1.30 0.60 2.79 10 / 99 0.99 0.43 2.28 3 / 41 0.76 0.22 2.59 
Missing values imputed via multiple imputation, patient numbers may thus be rounded. Effects significant at level α=0.05 are marked in bold. Patients were excluded from a particular analysis if the 
medication they received provided ≤ 20 patients for that analysis or if there were no deaths reported for that specific medication. 
CI, confidence interval; CTD, connective tissue diseases; CVD, cardiovascular disease; DA, disease activity; DMARD, disease modifying antirheumatic drugs; GC, glucocorticoids; IJD, inflammatory joint 
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Supplementary table 10. Multivariable logistic regression analysis of factors associated with COVID-19-related death stratified by age (> 65 years vs. ≤ 65 years) 
 > 65 years ≤ 65 years 
N deaths/patients (%) 266 / 1140 (23.3%) 118 / 2565 (4.6%) 
 N deaths/patients OR 95% CI N deaths/patients OR 95% CI 
Male sex (vs. female) 121 / 437 1.43 1.09 1.87 40 / 751 1.32 0.74 2.33 
Ever smoked (vs. never)  105 / 388 1.04 0.75 1.44 35 / 534 1.63 1.02 2.60 
Comorbidities 
Hypertension alone or CVD alone 103 / 544 0.85 0.53 1.36 52 / 627 2.04 1.38 3.01 
Hypertension and CVD 77 / 210 1.81 0.99 3.31 12 / 91 2.16 1.09 4.31 
Chronic lung disease 102 / 320 1.62 1.09 2.40 35 / 401 1.79 1.31 2.45 
Chronic kidney disease 53 / 158 1.43 0.75 2.75 23 / 100 3.78 2.24 6.37 
Diabetes mellitus 75 / 251 1.39 0.91 2.12 21 / 257 1.21 0.66 2.21 
Rheumatic disease 
Rheumatoid arthritis 129 / 537 1 [Reference] 40 / 850 1 [Reference] 
Systemic lupus erythematosus 8 / 47 0.54 0.26 1.11 28 / 344 1.24 0.66 2.34 
Vasculitis 55 / 192 0.77 0.55 1.09 12 / 133 0.91 0.46 1.78 
Other connective tissue diseases 32 / 147 0.66 0.51 0.85 21 / 326 0.75 0.37 1.54 
Psoriasis arthritis 12 / 85 0.73 0.52 1.03 7 / 344 0.58 0.24 1.37 
Spondyloarthritis 9 / 38 0.81 0.37 1.76 6 / 385 0.59 0.21 1.71 
Other inflammatory arthritis or 
non-systemic JIA 
8 / 33 0.71 0.36 1.39 2 / 76 0.67 0.31 1.44 
Other rheumatic diseases (not IJDs 
/ CTDs / vasculitis) 
17 / 83 0.45 0.29 0.69 7 / 146 0.58 0.25 1.33 
High/moderate/severe  disease 
activity (DA) vs. remission/low DA 
59 / 191 1.53 0.98 2.41 50 / 531 2.20 1.38 3.50 
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Methotrexate  41 / 242 1 [Reference] 6 / 353 1 [Reference] 
No DMARD therapy  96 / 352 2.07 1.45 2.96 28 / 387 3.82 1.42 10.27 
Leflunomide 7 / 38 0.98 0.38 2.55 5 / 52 3.90 1.12 13.61 
Antimalarials  13 / 113 0.68 0.38 1.21 14 / 313 2.13 0.71 6.39 
Sulfasalazine 28 / 61 3.89 1.60 9.48 5 / 83 3.22 1.14 9.06 
Immunosuppressants 18 / 55 2.74 1.51 4.97 20 / 221 1.90 0.70 5.20 
Rituximab 24 / 52 3.84 1.93 7.66 18 / 140 5.29 1.34 20.85 
Other b/tsDMARDs 39 / 234 0.92 0.61 1.38 22 / 1026 1.27 0.46 3.48 
Glucocorticoids (GCs) 
No GCs 118 / 606 1 [Reference] 47 / 1811 1 [Reference] 
GCs 1-10mg/d 117 / 443 1.19 0.84 1.70 54 / 619 2.10 1.19 3.71 
GCs > 10 mg/d 32 / 91 1.35 0.79 2.31 17 / 135 2.24 1.32 3.79 
Missing values imputed via multiple imputation, patient numbers may thus be rounded. Effects significant at level α=0.05 are marked in bold. Patients were excluded from a particular 
analysis if the medication they received provided ≤ 20 patients for that analysis or if there were no deaths reported for that specific medication. 
CI, confidence interval; CTD, connective tissue diseases; CVD, cardiovascular disease; DA, disease activity; DMARD, disease modifying antirheumatic drugs; GC, glucocorticoids; IJD, 
inflammatory joint diseases;  IL, interleukin; JIA, juvenile idiopathic arthritis; N, number; OR, odds ratio; SLE, systemic lupus erythematosus; TNF; tumour necrosis factor; tsDMARD, 
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Supplementary table 11. Multivariable logistic regression analysis of factors associated with COVID-19-related death stratified by sex 
 Male sex Female sex 
N deaths/patients (%) 161 / 1188 (13.6%) 223 / 2517 (8.9%) 
 N deaths/patients OR 95% CI N deaths/patients OR 95% CI 
Age, years 
Age ≤ 65 40 / 751 1 [Reference] 78 / 1814 1 [Reference] 
65 years < Age ≤ 75  55 / 252 3.81 1.96 7.41 54 / 392 2.65 1.62 4.32 
Age > 75 66 / 185 6.80 2.88 16.07 91 / 311 6.21 4.50 8.56 
Ever smoked (vs. never)  72 / 399 1.08 0.62 1.91 67 / 523 1.34 0.93 1.94 
Comorbidities 
Hypertension alone or CVD alone 66 / 385 1.16 0.89 1.50 89 / 765 1.24 0.83 1.85 
Hypertension and CVD 43 / 145 1.87 1.19 2.95 46 / 156 2.06 1.36 3.13 
Chronic lung disease 53 / 232 1.41 0.74 2.68 84 / 489 1.95 1.47 2.60 
Chronic kidney disease 30 / 104 1.26 0.59 2.71 46 / 155 2.03 1.13 3.64 
Diabetes mellitus 46 / 193 1.80 1.14 2.86 50 / 315 1.12 0.66 1.90 
Rheumatic disease 
Rheumatoid arthritis 55 / 347 1 [Reference] 114 / 1040 1 [Reference] 
Systemic lupus erythematosus 10 / 47 1.91 0.81 4.50 26 / 344 0.99 0.51 1.92 
Vasculitis 35 / 138 0.95 0.33 2.69 32 / 187 0.69 0.39 1.24 
Other connective tissue diseases 21 / 121 0.96 0.55 1.68 32 / 352 0.66 0.44 1.01 
Psoriasis arthritis 13 / 200 0.95 0.50 1.83 6 / 229 0.43 0.27 0.70 
Spondyloarthritis 10 / 202 0.82 0.29 2.31 5 / 221 0.53 0.17 1.64 
Other inflammatory arthritis or 
non-systemic JIA 
3 / 35 0.41 0.07 2.31 7 / 74 1.19 0.55 2.58 
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Other rheumatic diseases (not IJDs 
/ CTDs / vasculitis) 
16 / 112 0.49 0.30 0.79 8 / 117 0.50 0.29 0.89 
High/moderate/severe  disease 
activity (DA) vs. remission/low DA 
34 / 204 1.69 1.18 2.42 75 / 518 1.99 1.16 3.41 
Medication 
Methotrexate 23 / 206 1 [Reference] 24 / 389 1 [Reference] 
No DMARD therapy  61 / 280 2.25 1.16 4.37 63 / 459 2.19 1.13 4.24 
Leflunomide 5 / 28 1.57 0.82 3.02 7 / 62 1.79 0.82 3.89 
Antimalarials  61 / 280 0.86 0.36 2.04 63 / 459 1.19 0.66 2.15 
Sulfasalazine 16 / 52 4.71 1.92 11.54 17 / 92 3.26 0.93 11.40 
Immunosuppressants 14 / 79 2.02 1.15 3.54 24 / 197 2.41 1.20 4.82 
Rituximab 16 / 60 3.09 1.03 9.30 26 / 132 5.40 3.06 9.52 
Other b/tsDMARDs 19 / 425 0.64 0.37 1.10 42 / 835 1.34 0.75 2.39 
Glucocorticoids (GCs) 
No GCs 76 / 781 1 [Reference] 89 / 1636 1 [Reference] 
GCs 1-10mg/d 65 / 319 1.07 0.61 1.87 105 / 744 1.71 1.17 2.52 
GCs > 10 mg/d 20 / 88 1.20 0.67 2.17 29 / 138 2.23 1.34 3.73 
Missing values imputed via multiple imputation, patient numbers may thus be rounded. Effects significant at level α=0.05 are marked in bold. Patients were excluded from a particular 
analysis if the medication they received provided ≤ 20 patients for that analysis or if there were no deaths reported for that specific medication. 
CI, confidence interval; CTD, connective tissue diseases; CVD, cardiovascular disease; DA, disease activity; DMARD, disease modifying antirheumatic drugs; GC, glucocorticoids; IJD, 
inflammatory joint diseases;  IL, interleukin; JIA, juvenile idiopathic arthritis; N, number; OR, odds ratio; SLE, systemic lupus erythematosus; TNF; tumour necrosis factor; tsDMARD, 
targeted synthetic disease modifying antirheumatic drugs. 
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Supplementary table 12. Multivariable logistic regression analysis of factors associated with COVID-19-related death stratified by smoking habits 
 Ever smoked Never smoked 
N deaths/patients (%) 140 / 922 (15.2%) 244 / 2783 (8.8%) 
 N deaths/patients OR 95% CI N deaths/patients OR 95% CI 
Age, years 
Age ≤ 65 35 / 534 1 [Reference] 83 / 2031 1 [Reference] 
65 years < Age ≤ 75  47 / 226 2.79 1.70 4.58 62 / 418 3.18 2.06 4.91 
Age > 75 58 / 162 6.43 3.33 12.42 99 / 334 6.33 4.32 9.27 
Male sex (vs. female) 72 / 399 1.30 0.72 2.35 89 / 789 1.46 1.14 1.88 
Comorbidities 
Hypertension alone or CVD alone 57 / 338 1.01 0.67 1.50 98 / 812 1.32 0.94 1.86 
Hypertension and CVD 36 / 124 1.53 0.84 2.79 52 / 177 2.08 1.32 3.27 
Chronic lung disease 62 / 271 1.49 0.78 2.84 74 / 450 1.93 1.45 2.58 
Chronic kidney disease 21 / 87 0.74 0.38 1.42 55 / 172 2.72 1.56 4.73 
Diabetes mellitus 39 / 158 1.48 0.80 2.74 57 / 350 1.33 0.79 2.22 
Rheumatic disease 
Rheumatoid arthritis 71 / 388 1 [Reference] 98 / 999 1 [Reference] 
Systemic lupus erythematosus 11 / 62 1.30 0.60 2.84 26 / 329 1.12 0.64 1.94 
Vasculitis 18 / 90 0.42 0.19 0.92 49 / 235 0.96 0.67 1.37 
Other connective tissue diseases 16 / 103 0.71 0.34 1.48 37 / 370 0.68 0.42 1.10 
Psoriasis arthritis 6 / 111 0.60 0.24 1.54 13 / 318 0.70 0.44 1.12 
Spondyloarthritis 3 / 80 0.32 0.08 1.29 12 / 343 0.82 0.37 1.85 
Other inflammatory arthritis or 
non-systemic JIA 
5 / 27 0.65 0.21 2.02 5 / 82 0.84 0.44 1.58 
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Other rheumatic diseases (not IJDs 
/ CTDs / vasculitis) 
12 / 73 0.59 0.26 1.31 12 / 156 0.40 0.25 0.66 
High/moderate/severe  disease 
activity (DA) vs. remission/low DA 
32 / 171 1.45 0.85 2.45 77 / 551 2.11 1.31 3.40 
Medication 
Methotrexate 15 / 145 1 [Reference] 33 / 450 1 [Reference] 
No DMARD therapy  43 / 221 2.35 1.15 4.83 82 / 518 2.18 1.43 3.30 
Leflunomide 5 / 21 1.41 0.39 5.12 8 / 69 1.52 0.68 3.39 
Antimalarials  13 / 93 1.52 0.68 3.38 14 / 334 0.75 0.46 1.21 
Sulfasalazine 21 / 56 6.15 2.23 16.94 12 / 89 2.16 0.81 5.73 
Immunosuppressants 12 / 55 3.89 1.53 9.85 26 / 221 1.76 0.96 3.23 
Rituximab 12 / 46 3.95 1.29 12.10 30 / 146 4.14 2.16 7.93 
Other b/tsDMARDs 20 / 289 1.04 0.48 2.26 41 / 971 0.90 0.59 1.35 
Glucocorticoids (GCs) 
No GCs 67 / 604 1 [Reference] 98 / 1813 1 [Reference] 
GCs 1-10mg/d 57 / 260 1.52 0.91 2.53 114 / 802 1.35 0.88 2.05 
GCs > 10 mg/d 16 / 57 2.53 1.33 4.80 33 / 168 1.48 0.93 2.35 
Missing values imputed via multiple imputation, patient numbers may thus be rounded. Effects significant at level α=0.05 are marked in bold. Patients were excluded from a particular 
analysis if the medication they received provided ≤ 20 patients for that analysis or if there were no deaths reported for that specific medication. 
CI, confidence interval; CTD, connective tissue diseases; CVD, cardiovascular disease; DA, disease activity; DMARD, disease modifying antirheumatic drugs; GC, glucocorticoids; IJD, 
inflammatory joint diseases;  IL, interleukin; JIA, juvenile idiopathic arthritis; N, number; OR, odds ratio; SLE, systemic lupus erythematosus; TNF; tumour necrosis factor; tsDMARD, 
targeted synthetic disease modifying antirheumatic drugs. 
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Supplementary table 13. Multivariable logistic regression analysis of factors associated with COVID-19-related death stratified by heart disease (hypertension and/or 
cardiovascular disease) 
 Heart disease No heart disease 
N deaths/patients (%) 242 / 1439 (16.8%) 384 / 3705 (10.4%) 
 N deaths/patients OR 95% CI N deaths/patients OR 95% CI 
Age, years 
Age ≤ 65 63 / 711 1 [Reference] 53 / 1833 1 [Reference] 
65 years < Age ≤ 75  58 / 367 1.68 1.12 2.52 49 / 270 5.98 3.72 9.63 
Age > 75 121 / 361 4.77 3.08 7.40 36 / 134 7.65 5.24 11.16 
Male sex (vs. female) 108 / 525 1.59 1.23 2.06 51 / 655 1.25 0.76 2.05 
Ever smoked (vs. never)  93 / 458 1.13 0.82 1.56 46 / 457 1.48 0.94 2.34 
Comorbidities 
Chronic lung disease 84 / 352 1.56 1.15 2.12 51 / 362 2.39 1.77 3.24 
Chronic kidney disease 58 / 190 1.58 0.94 2.67 18 / 67 2.83 1.04 7.71 
Diabetes mellitus 75 / 358 1.33 0.84 2.12 20 / 145 1.85 1.38 2.48 
Rheumatic disease 
Rheumatoid arthritis 105 / 572 1 [Reference] 63 / 805 1 [Reference] 
Systemic lupus erythematosus 24 / 154 1.16 0.55 2.46 11 / 235 1.04 0.54 2.02 
Vasculitis 39 / 168 0.61 0.36 1.01 27 / 155 1.12 0.69 1.81 
Other connective tissue diseases 36 / 201 0.79 0.60 1.02 16 / 264 0.59 0.31 1.12 
Psoriasis arthritis 13 / 152 0.70 0.45 1.10 6 / 273 0.60 0.30 1.19 
Spondyloarthritis 6 / 87 0.51 0.17 1.51 9 / 336 0.87 0.43 1.74 
Other inflammatory arthritis or 
non-systemic JIA 
8 / 34 1.30 0.66 2.55 2 / 73 0.48 0.14 1.70 
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Other rheumatic diseases (not IJDs 
/ CTDs / vasculitis) 
16 / 100 0.45 0.30 0.68 8 / 128 0.54 0.19 1.51 
High/moderate/severe  disease 
activity (DA) vs. remission/low DA 
66 / 283 1.92 1.01 3.63 42 / 432 1.92 1.31 2.83 
Medication 
Methotrexate 14 / 352 1 [Reference] 33 / 238 1 [Reference] 
No DMARD therapy  91 / 372 2.14 1.37 3.35 32 / 361 2.09 1.10 3.97 
Leflunomide 5 / 40 0.79 0.24 2.61 7 / 49 3.49 1.23 9.89 
Antimalarials  20 / 168 1.10 0.62 1.96 6 / 254 0.64 0.25 1.69 
Sulfasalazine 18 / 64 2.78 1.08 7.15 14 / 77 4.82 1.92 12.08 
Immunosuppressants 21 / 117 1.82 1.02 3.23 17 / 158 2.25 0.79 6.38 
Rituximab 19 / 68 2.49 1.25 4.96 22 / 121 5.86 2.34 14.68 
Other b/tsDMARDs 35 / 377 0.96 0.59 1.54 26 / 877 1.08 0.53 2.20 
Glucocorticoids (GCs) 
No GCs 96 / 816 1 [Reference] 69 / 1584 1 [Reference] 
GCs 1-10mg/d 114 / 510 1.62 1.02 2.56 53 / 541 1.16 0.65 2.07 
GCs > 10 mg/d 32 / 112 1.84 1.20 2.82 17 / 112 1.62 0.91 2.87 
Missing values imputed via multiple imputation, patient numbers may thus be rounded. Effects significant at level α=0.05 are marked in bold. Patients were excluded from a particular 
analysis if the medication they received provided ≤ 20 patients for that analysis or if there were no deaths reported for that specific medication. 
CI, confidence interval; CTD, connective tissue diseases; CVD, cardiovascular disease; DA, disease activity; DMARD, disease modifying antirheumatic drugs; GC, Glucocorticoids; IJD, 
inflammatory joint diseases;  IL, interleukin; JIA, juvenile idiopathic arthritis; N, number; OR, odds ratio; SLE, Systemic lupus erythematosus; TNF; tumour necrosis factor; tsDMARD, 
targeted synthetic disease modifying antirheumatic drugs. 
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Supplementary table 14. Multivariable logistic regression analysis of factors associated with COVID-19-related death stratified by chronic lung disease 
 Chronic lung disease No chronic lung disease 
N deaths/patients (%) 136 / 721 (18.9%) 248 / 2984 (8.3%) 
 N deaths/patients OR 95% CI N deaths/patients OR 95% CI 
Age, years 
Age ≤ 65 35 / 401 1 [Reference] 84 / 2164 1 [Reference] 
65 years < Age ≤ 75  48 / 189 3.58 2.40 5.33 61 / 456 3.08 2.18 4.36 
Age > 75 54 / 131 8.34 6.29 11.05 103 / 365 5.82 3.43 9.90 
Male sex (vs. female) 53 / 232 1.02 0.47 2.22 108 / 956 1.60 1.24 2.07 
Ever smoked (vs. never)  62 / 271 1.23 0.68 2.24 77 / 651 1.24 0.93 1.66 
Comorbidities 
Hypertension alone or CVD alone 51 / 260 0.92 0.67 1.27 104 / 890 1.43 1.05 1.94 
Hypertension and CVD 34 / 97 1.51 0.84 2.73 55 / 204 2.21 1.50 3.27 
Chronic kidney disease 21 / 64 0.96 0.32 2.82 55 / 194 2.04 1.22 3.43 
Diabetes mellitus 38 / 140 1.40 0.61 3.21 58 / 368 1.44 1.05 1.96 
Rheumatic disease 
Rheumatoid arthritis 65 / 298 1 [Reference] 104 / 1089 1 [Reference] 
Systemic lupus erythematosus 5 / 58 0.55 0.18 1.66 31 / 333 1.42 0.81 2.50 
Vasculitis 18 / 66 0.87 0.44 1.72 49 / 259 0.75 0.57 1.00 
Other connective tissue diseases 35 / 169 1.21 0.66 2.19 19 / 304 0.46 0.30 0.71 
Psoriasis arthritis 4 / 44 1.19 0.45 3.14 15 / 385 0.54 0.40 0.75 
Spondyloarthritis 4 / 49 0.81 0.43 1.55 11 / 374 0.60 0.26 1.35 
Other inflammatory arthritis or 
non-systemic JIA 
4 / 16 1.61 0.53 4.85 6 / 94 0.55 0.26 1.19 
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Other rheumatic diseases (not IJDs 
/ CTDs / vasculitis) 
6 / 40 0.73 0.24 2.21 18 / 189 0.40 0.24 0.69 
High/moderate/severe  disease 
activity (DA) vs. remission/low DA 
43 / 173 1.70 1.01 2.87 66 / 549 1.97 1.27 3.04 
Medication 
Methotrexate 16 / 110 1 [Reference] 31 / 485 1 [Reference] 
No DMARD therapy  35 / 138 2.28 1.31 3.95 89 / 601 2.17 1.39 3.39 
Leflunomide 5 / 23 2.21 1.21 4.03 7 / 67 1.44 0.68 3.07 
Antimalarials  12 / 78 2.03 0.68 6.06 15 / 348 0.73 0.38 1.41 
Sulfasalazine 10 / 33 2.97 1.19 7.39 23 / 111 4.20 1.83 9.65 
Immunosuppressants 17 / 93 2.74 1.99 3.78 21 / 183 1.68 0.86 3.28 
Rituximab 20 / 65 4.95 1.59 15.39 23 / 127 4.08 1.99 8.39 
Other b/tsDMARDs 21 / 183 1.22 0.69 2.16 40 / 1077 0.90 0.52 1.54 
Glucocorticoids (GCs) 
No GCs 52 / 406 1 [Reference] 113 / 2012 1 [Reference] 
GCs 1-10mg/d 68 / 258 1.95 1.30 2.91 103 / 804 1.23 0.77 1.95 
GCs > 10 mg/d 17 / 58 1.70 0.96 3.00 32 / 168 1.65 0.93 2.92 
Missing values imputed via multiple imputation, patient numbers may thus be rounded. Effects significant at level α=0.05 are marked in bold. Patients were excluded from a particular 
analysis if the medication they received provided ≤ 20 patients for that analysis or if there were no deaths reported for that specific medication. 
CI, confidence interval; CTD, connective tissue diseases; CVD, cardiovascular disease; DA, disease activity; DMARD, disease modifying antirheumatic drugs; GC, glucocorticoids; IJD, 
inflammatory joint diseases;  IL, interleukin; JIA, juvenile idiopathic arthritis; N, number; OR, odds ratio; SLE, systemic lupus erythematosus; TNF; tumour necrosis factor; tsDMARD, 
targeted synthetic disease modifying antirheumatic drugs. 
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Supplementary table 15. Multivariable logistic regression analysis of factors associated with COVID-19-related death stratified by disease activity 
 Moderate / severe disease activity Low disease activity / remission 
N deaths/patients (%) 109 / 722 (15.1%) 275 / 2983 (9.2%) 
 N deaths/patients OR 95% CI N deaths/patients OR 95% CI 
Age, years 
Age ≤ 65 50 / 531 1 [Reference] 69 / 2035 1 [Reference] 
65 years < Age ≤ 75  30 / 120 2.52 1.22 5.23 80 / 524 3.47 2.40 5.01 
Age > 75 30 / 72 3.92 1.99 7.74 127 / 424 7.50 4.65 12.08 
Male sex (vs. female) 34 / 204 1.18 0.62 2.22 127 / 984 1.50 1.15 1.97 
Ever smoked (vs. never)  32 / 171 1.09 0.64 1.86 108 / 751 1.25 0.92 1.70 
Comorbidities 
Hypertension alone or CVD alone 43 / 227 1.32 0.70 2.49 112 / 923 1.17 0.88 1.55 
Hypertension and CVD 24 / 59 3.26 1.33 8.03 65 / 242 1.71 1.08 2.73 
Chronic lung disease 43 / 173 1.78 1.20 2.64 93 / 548 1.69 1.16 2.46 
Chronic kidney disease 30 / 61 3.62 1.81 7.25 47 / 197 1.18 0.58 2.39 
Diabetes mellitus 25 / 115 0.85 0.39 1.84 71 / 393 1.57 1.03 2.39 
Rheumatic disease 
Rheumatoid arthritis 46 / 283 1 [Reference] 123 / 1104 1 [Reference] 
Systemic lupus erythematosus 17 / 77 1.42 0.59 3.41 19 / 315 0.96 0.57 1.59 
Vasculitis 18 / 52 1.32 0.59 2.92 49 / 273 0.68 0.44 1.04 
Other connective tissue diseases 21 / 108 1.17 0.59 2.29 32 / 365 0.63 0.45 0.88 
Psoriasis arthritis 5 / 79 0.53 0.16 1.77 15 / 350 0.72 0.41 1.27 
Spondyloarthritis 3 / 79 0.45 0.15 1.34 12 / 344 0.77 0.30 1.97 
Other inflammatory arthritis or 
non-systemic JIA 
1 / 19 0.68 0.10 4.50 9 / 90 0.77 0.40 1.49 
BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
Supplemental material placed on this supplemental material which has been supplied by the author(s) Ann Rheum Dis
 doi: 10.1136/annrheumdis-2020-219498–13.:10 2021;Ann Rheum Dis, et al. Strangfeld A
41 
 
Other rheumatic diseases (not IJDs 
/ CTDs / vasculitis) 
1 / 45 0.01 0.00 1834.66 23 / 184 0.64 0.46 0.88 
Medication 
Methotrexate 5 / 92 1 [Reference] 42 / 503 1 [Reference] 
No DMARD therapy  27 / 134 4.64 1.64 13.15 97 / 605 1.93 1.33 2.78 
Leflunomide 6 / 19 6.96 2.64 18.39 6 / 71 0.96 0.41 2.25 
Antimalarials  8 / 60 2.28 0.88 5.92 19 / 366 0.96 0.57 1.60 
Sulfasalazine 6 / 25 7.44 1.35 40.89 27 / 119 3.27 1.59 6.72 
Immunosuppressants 19 / 83 3.95 1.24 12.59 19 / 193 1.98 1.09 3.58 
Rituximab 12 / 52 3.50 1.11 11.07 30 / 140 5.16 3.00 8.89 
Other b/tsDMARDs 25 / 261 2.76 1.14 6.70 36 / 999 0.76 0.49 1.20 
Glucocorticoids (GCs) 
No GCs 28 / 336 1 [Reference] 136 / 2081 1 [Reference] 
GCs 1-10mg/d 51 / 266 1.61 0.86 3.02 119 / 797 1.44 0.94 2.19 
GCs > 10 mg/d 30 / 120 1.71 0.94 3.10 19 / 105 1.69 0.80 3.59 
Missing values imputed via multiple imputation, patient numbers may thus be rounded. Effects significant at level α=0.05 are marked in bold. Patients were excluded from a particular 
analysis if the medication they received provided ≤ 20 patients for that analysis or if there were no deaths reported for that specific medication. 
CI, confidence interval; CTD, connective tissue diseases; CVD, cardiovascular disease; DA, disease activity; DMARD, disease modifying antirheumatic drugs; GC, Glucocorticoids; IJD, 
inflammatory joint diseases;  IL, interleukin; JIA, juvenile idiopathic arthritis; N, number; OR, odds ratio; SLE, Systemic lupus erythematosus; TNF; tumour necrosis factor; tsDMARD, 
targeted synthetic disease modifying antirheumatic drugs. 
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Supplementary table 16. Multivariable logistic regression analysis of factors associated with COVID-19-related death stratified by glucocorticoid use 
 Glucocorticoids No glucocorticoids 
N deaths/patients (%) 219 / 1288 (17.0%) 165 / 2417 (6.8%) 
 N deaths/patients OR 95% CI N deaths/patients OR 95% CI 
Age, years 
Age ≤ 65 71 / 754 1 [Reference] 47 / 1811 1 [Reference] 
65 years < Age ≤ 75  52 / 265 1.80 1.21 2.68 57 / 379 5.54 3.17 9.70 
Age > 75 97 / 269 4.67 3.25 6.71 61 / 227 8.75 4.48 17.10 
Male sex (vs. female) 85 / 407 1.16 0.86 1.57 76 / 781 1.71 1.16 2.51 
Ever smoked (vs. never)  73 / 318 1.25 0.94 1.65 67 / 604 1.12 0.74 1.69 
Comorbidities 
Hypertension alone or CVD alone 94 / 474 1.43 0.92 2.23 61 / 676 0.95 0.67 1.36 
Hypertension and CVD 54 / 154 1.87 1.09 3.22 35 / 147 1.86 1.28 2.71 
Chronic lung disease 84 / 316 2.03 1.43 2.89 52 / 406 1.47 0.89 2.44 
Chronic kidney disease 51 / 151 1.79 0.99 3.22 25 / 108 1.58 0.71 3.49 
Diabetes mellitus 55 / 215 1.32 0.76 2.31 41 / 293 1.51 0.97 2.35 
Rheumatic disease 
Rheumatoid arthritis 91 / 516 1 [Reference] 78 / 871 1 [Reference] 
Systemic lupus erythematosus 26 / 198 1.20 0.63 2.31 10 /193 1.11 0.40 3.07 
Vasculitis 58 / 240 0.95 0.51 1.76 9 / 85 0.57 0.11 3.11 
Other connective tissue diseases 31 / 181 0.84 0.56 1.25 22 / 292 0.59 0.37 0.95 
Psoriasis arthritis 4 / 53 0.52 0.11 2.50 15 / 376 0.68 0.41 1.15 
Spondyloarthritis 3 / 38 0.69 0.27 1.76 12 / 385 0.68 0.28 1.68 
Other inflammatory arthritis or 
non-systemic JIA 
5 / 24 1.04 0.27 3.96 5 / 85 0.58 0.26 1.30 
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Other rheumatic diseases (not IJDs 
/ CTDs / vasculitis) 
7 / 69 0.48 0.17 1.33 17 / 160 0.51 0.28 0.91 
High/moderate/severe  disease 
activity (DA) vs. remission/low DA 
80 / 386 1.95 1.30 2.92 28 / 336 1.74 0.98 3.08 
Medication 
Methotrexate 18 / 212 1 [Reference] 29 / 383 1 [Reference] 
No DMARD therapy  74 / 296 3.11 2.12 4.57 50 / 444 1.72 0.94 3.17 
Leflunomide 9 / 43 3.40 1.83 6.34 3 / 47 0.52 0.17 1.63 
Antimalarials  18 / 137 1.81 1.19 2.77 9 / 289 0.59 0.26 1.33 
Sulfasalazine 11 / 48 3.17 1.22 8.27 22 / 96 4.00 1.72 9.28 
Immunosuppressants 24 / 176 2.27 1.61 3.19 14 / 100 3.26 1.45 7.31 
Rituximab 30 / 99 5.52 2.13 14.33 12 / 94 3.41 1.57 7.41 
Other b/tsDMARDs 35 / 289 1.78 1.13 2.81 26 / 971 0.62 0.35 1.08 
Missing values imputed via multiple imputation, patient numbers may thus be rounded. Effects significant at level α=0.05 are marked in bold. Patients were excluded from a particular 
analysis if the medication they received provided ≤ 20 patients for that analysis or if there were no deaths reported for that specific medication. 
CI, confidence interval; CTD, connective tissue diseases; CVD, cardiovascular disease; DA, disease activity; DMARD, disease modifying antirheumatic drugs; GC, glucocorticoids; IJD, 
inflammatory joint diseases;  IL, interleukin; JIA, juvenile idiopathic arthritis; N, number; OR, odds ratio; SLE, systemic lupus erythematosus; TNF; tumour necrosis factor; tsDMARD, 
targeted synthetic disease modifying antirheumatic drugs. 
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COVID-19-related death in rheumatic diseases 
This is the lay version of a paper published on behalf of the COVID-19 Global Rheumatology Alliance 
Consortium. It examines COVID-19-related death in people with rheumatic diseases. The original publication 
can be downloaded from the EULAR website: www.eular.org. 
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Introduction 
EULAR gives advice to doctors, nurses and patients about the best way to treat and manage rheumatic 
diseases. As part of the current global effort to understand and combat COVID-19, EULAR gave financial 
support to this registry project. 
 
What do we already know? 
There are more than 200 rheumatic diseases, including rheumatoid arthritis, spondyloarthritis, and systemic 
lupus erythematosus. Many of these diseases are autoimmune conditions that cause inflammation in the 
body. Rheumatic diseases typically affect joints, muscle, or connective tissue. They can also affect a 
person’s internal organs.  
 
People with rheumatic diseases are more prone to infection. This can be because of the disease itself and 
the way it affects the immune system, but also affected by some of the medicines used to treat the rheumatic 
disease. COVID-19 is the disease caused by a new type of coronavirus called severe acute respiratory 
syndrome coronavirus-2 (SARS-CoV-2). Clinical information for people with COVID-19 who have a 
rheumatic disease is limited, especially about factors that might make them more likely to die from the 
infection.  
 
What does the paper say? 
The registry collected information on 3729 people with rheumatic disease who had either a confirmed or 
highly likely case of COVID-19, or had symptoms of this infection. In total, 390 people died – just over 10%. 
The authors looked to see if there were any common factors in the people who died compared to those who 
recovered from the COVID-19 infection.  
• Older age and male sex are associated with COVID-19-related death. 
Of those who died, over two-thirds were over the age of 65. The risk of dying was even higher in 
people in over the age of 75, and for men compared to women. This is similar to what has been 
found in the general population.    
• Comorbidities are more common in people who die from COVID-19.  
Across all 3729 people included, most people had at least one other disease (comorbidity). The most 
common were hypertension (high blood pressure), chronic lung disease, and obesity. In the whole 
group, 21% of people had three or more comorbidities. When the authors looked only at the people 
who had died, 43% had three or more comorbidities. This is similar to what has been found in the 
general population.  
• Cardiovascular and chronic lung disease are more common in people dying from COVID-19.  
Other factors associated with dying from COVID-19 included chronic lung disease, or having 
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cardiovascular disease combined with hypertension. Chronic kidney disease was also a risk for 
people with connective tissue disease or vasculitis, but did not increase the risk of death for people 
with other types of rheumatic disease.  
• Disease-specific factors are associated with COVID-19-related death. 
People with moderate or high disease activity were more likely to die from COVID-19 than those with 
low disease activity or people who were in remission (no current signs and symptoms of their 
rheumatic disease).  
• Certain medications are associated with COVID-19-related death. 
People taking rituximab or sulfasalazine were more likely to die from COVID-19. A similar 
association was seen for a mixed group of immunosuppressants (azathioprine, cyclophosphamide, 
ciclosporin, mycophenolate and tacrolimus) compared to those using immunomodulators such as 
disease-modifying anti-rheumatic drugs (often shortened to DMARDs). However, the numbers were 
too low to allow individual analysis by immunosuppressive drug, making it difficult to interpret these 
results. Moderate to high doses of glucocorticoids (steroids) – more than 10 mg per day – were also 
associated with a higher risk of dying across all rheumatic diseases.  
What does this mean for me? 
These finding will help patients and doctors reach a shared understanding of risk of COVID-19 severe 
outcomes in patients with RMDs. If you have been in contact with a COVID-19 patient or have symptoms of 
COVID-19, you should contact your local health authorities and your rheumatologist. Generally, patients with 
RMD should continue to comply with all preventive and control measures and vaccination efforts prescribed 
by the health authorities in their countries, such as hand hygiene, wearing masks (ideally FFP2 masks) and 
holding distance of at least 2 meters from others. 
 
Summary 
Overall, the papers highlights that the risk of dying from COVID-19 varies according to people’s underlying 
disease activity and what medicine they are taking. It is important for people with a rheumatic disease to 
continue to control their disease activity with DMARDs, but preferably without increasing the dose of any 
glucocorticoids, if possible. Withdrawal of effective treatments should be based on sound evidence, even 
during a pandemic. 
 
If you have any questions or concerns about your disease or your medication, you should speak to a health 








The EULAR COVID-19 Database is based on rheumatologists and other clinicians voluntarily reporting 
cases, meaning that patients included do not necessarily represent the majority of patients with RMDs and 
COVID-19, but those who their doctors reported data to the database. Additionally, this database does not 
account for non-COVID-19 patients. Therefore, results cannot be directly extrapolated to the entire 
population of patients with RMDs and COVID-19, and should be interpreted cautiously.  
